var title_f32_53_33616="Retinal vein occlusion";
var content_f32_53_33616=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F72976&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F72976&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Retinal vein occlusion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 312px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Don C Bienfang, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_53_33616=[""].join("\n");
var outline_f32_53_33616=null;
var title_f32_53_33617="Duodenal carcinoid EUS";
var content_f32_53_33617=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F51383&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F51383&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Carcinoid tumor in the duodenum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 315px; height: 322px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endosonographic view of a duodenal carcinoid tumor (arrow). Carcinoids are hypo- or isoechoic with regular margins. They arise from the mucosa/lamina propria (second layer of the GI tract) and can invade the submucosal layer.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mary Lee Krinsky, DO and Kenneth Binmoeller, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_53_33617=[""].join("\n");
var outline_f32_53_33617=null;
var title_f32_53_33618="Ottawa ankle rules";
var content_f32_53_33618=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F69818&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F69818&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ottawa ankle rules",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 578px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ankle films: A series of ankle x ray films is required only if there is any pain in malleolar zone and any of these findings: Bone tenderness at A; Bone tenderness at B; Inability to bear weight both immediately and in the emergency department. Foot films: A series of foot x ray films is required only if there is any pain in mid- foot zone and any of these findings: Bone tenderness at C; Bone tenderness at D; Inability to bear weight both immediately and in the emergency department.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified from Stiell, IG, McKnight, RD, Greenberg, GH, et al, JAMA 1994; 271:827.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_53_33618=[""].join("\n");
var outline_f32_53_33618=null;
var title_f32_53_33619="Fidaxomicin: Patient drug information";
var content_f32_53_33619=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Fidaxomicin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/28/15812?source=see_link\">",
"     see \"Fidaxomicin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13120424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Dificid&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F14732997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Dificid&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F12930074\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat some causes of very loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F12990533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3473521",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to fidaxomicin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F12990530\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F12930077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals and good mouth care may help. Older children may suck hard, sugar-free candy.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F12990534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698607",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Black, tarry, or bloody stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F12930075\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F12990531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F13936061\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F12990535\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16783 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-6A12EA632A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_53_33619=[""].join("\n");
var outline_f32_53_33619=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13120424\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14732997\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12930074\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12990533\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12990530\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12930077\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12990534\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12930075\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12990531\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13936061\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12990535\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?15/28/15812?source=related_link\">",
"      Fidaxomicin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_53_33620="Amyloid goiter Congo red";
var content_f32_53_33620=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F56789&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F56789&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Amyloid goiter: Microscopic section with Congo red stain",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 271px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Microscopic section (Congo red and hematoxylin and eosin stains, magnification x 100) of the thyroid from a patient with an amyloid goiter stained with Congo red shows green birefringence under polarized light microscopy. Note deposition of amyloid material surrounding a thyroid follicule (F) and in the perivascular (V) space.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stephanie L Lee, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_53_33620=[""].join("\n");
var outline_f32_53_33620=null;
var title_f32_53_33621="Pemphigus vulgaris IIF";
var content_f32_53_33621=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F82839&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F82839&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Pemphigus vulgaris indirect immunofluorescence",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pemphigus vulgaris. Indirect immunofluorescence performed on monkey esophagus demonstrates intercellular IgG antibody deposition.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kristin M Leiferman, MD, Immunodermatology Laboratory, Department of Dermatology, University of Utah, Salt Lake City, Utah.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_53_33621=[""].join("\n");
var outline_f32_53_33621=null;
var title_f32_53_33622="Dexmedetomidine: Drug information";
var content_f32_53_33622=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dexmedetomidine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?33/52/34627?source=see_link\">",
"    see \"Dexmedetomidine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/6/37989?source=see_link\">",
"    see \"Dexmedetomidine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F158352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Precedex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F158353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Precedex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F158371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alpha;",
"      <sub>",
"       2",
"      </sub>",
"      -Adrenergic Agonist",
"     </li>",
"     <li>",
"      Sedative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F158356\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Errors have occurred due to misinterpretation of dosing information. Maintenance dose expressed as mcg/kg/",
"     <b>",
"      hour",
"     </b>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Individualized and titrated to desired clinical effect. Manufacturer recommends duration of infusion should not exceed 24 hours; however, randomized clinical trials have demonstrated efficacy and safety comparable to lorazepam and midazolam with longer-term infusions of up to approximately 5 days. (Pandharipande, 2007; Riker, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      ICU sedation:",
"     </b>",
"     I.V.: Initial: Loading infusion (optional; see",
"     <b>",
"      \"Note\"",
"     </b>",
"     below) of 1 mcg/kg over 10 minutes, followed by a maintenance infusion of 0.2-0.7 mcg/kg/",
"     <b>",
"      hour",
"     </b>",
"     ; adjust rate to desired level of sedation; titration no more frequently than every 30 minutes may reduce the incidence of hypotension (Gerlach, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     <i>",
"      Loading infusion:",
"     </i>",
"     Administration of a loading infusion may increase the risk of hemodynamic compromise. For this indication, the loading dose may be omitted.",
"     <i>",
"      Maintenance infusion:",
"     </i>",
"     Dosing ranges between 0.2-1.4 mcg/kg/",
"     <b>",
"      hour",
"     </b>",
"     have been reported during randomized controlled clinical trials (Pandharipande, 2007; Riker, 2009). Although infusion rates as high as 2.5 mcg/kg/",
"     <b>",
"      hour",
"     </b>",
"     have been used, it is thought that doses &gt;1.5 mcg/kg/",
"     <b>",
"      hour",
"     </b>",
"     do not add to clinical efficacy (Venn, 2003).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Procedural sedation:",
"     </b>",
"     I.V.: Initial: Loading infusion of 1 mcg/kg (or 0.5 mcg/kg for less invasive procedures [eg, ophthalmic]) over 10 minutes, followed by a maintenance infusion of 0.6 mcg/kg/",
"     <b>",
"      hour",
"     </b>",
"     , titrate to desired effect; usual range: 0.2-1 mcg/kg/",
"     <b>",
"      hour",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Fiberoptic intubation (awake):",
"     </b>",
"     I.V. Initial: Loading infusion of 1 mcg/kg over 10 minutes, followed by a maintenance infusion of 0.7 mcg/kg/",
"     <b>",
"      hour",
"     </b>",
"     until endotracheal tube is secured.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F158357\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      ICU sedation:",
"     </b>",
"     I.V.: Refer to adult dosing. Dosage reduction may need to be considered. No specific guidelines available. Dose selections should be cautious, at the low end of dosage range; titration should be slower, allowing adequate time to evaluate response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Procedural sedation:",
"     </b>",
"     I.V.: Refer to adult dosing: Initial: Loading infusion of 0.5 mcg/kg over 10 minutes; Maintenance infusion: Dosage reduction should be considered.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F158358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage reduction may need to be considered. No specific guidelines available.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F158359\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage reduction may need to be considered. No specific guidelines available.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F158336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Precedex&reg;: 100 mcg/mL (2 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F158321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F158338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer using a controlled infusion device. Advisable to use administration components made with synthetic or coated natural rubber gaskets. Parenteral products should be inspected visually for particulate matter and discoloration prior to administration. If loading dose used, administer over 10 minutes; may extend to 20 minutes to further reduce vasoconstrictive effects. Titration no more frequently than every 30 minutes may reduce the incidence of hypotension when used for ICU sedation (Gerlach, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block uica drugH1Div\" id=\"F14471305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     200 mcg in 50 mL (concentration: 4 mcg/mL) of NS",
"    </p>",
"   </div>",
"   <div class=\"block uicp drugH1Div\" id=\"F14471306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     4 mcg/mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F158377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR, NS, mannitol 20%, plasma substitute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Alfentanil, amikacin, aminophylline, amiodarone, ampicillin, ampicillin/sulbactam, azithromycin, aztreonam, bumetanide, butorphanol, calcium gluconate, cefazolin, cefepime, cefotaxime, cefotetan, cefoxitin, ceftazidime, cefuroxime, chlorpromazine, cimetidine, ciprofloxacin, cisatracurium, clindamycin, dexamethasone sodium phosphate, digoxin, diltiazem, diphenhydramine, dobutamine, dolasetron, dopamine, doxycycline, droperidol, enalaprilat, ephedrine, epinephrine, erythromycin, esmolol, etomidate, famotidine, fenoldopam, fentanyl, fluconazole, furosemide, gentamicin, granisetron, haloperidol, heparin, hydrocortisone sodium succinate, hydromorphone, hydroxyzine, inamrinone, isoproterenol, ketorolac, labetalol, levofloxacin, lidocaine, linezolid, lorazepam, magnesium sulfate, meperidine, methylprednisolone sodium succinate, metoclopramide, metronidazole, milrinone, nalbuphine, nitroglycerin, nitroprusside, norepinephrine, ondansetron, piperacillin, piperacillin/tazobactam, potassium chloride, procainamide, prochlorperazine, promethazine, propofol, ranitidine, remifentanil, rocuronium, sodium bicarbonate, sufentanil, sulfamethoxazole/trimethoprim, theophylline, ticarcillin/clavulanate, tobramycin, vancomycin, verapamil.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B, diazepam.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Ceftriaxone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Ceftriaxone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     May adsorb to certain types of natural rubber; use components made with synthetic or coated natural rubber gaskets whenever possible.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F158337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting; sedation prior to and/or during surgical or other procedures of nonintubated patients",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F158368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Unlabeled uses include premedication prior to anesthesia induction with thiopental; relief of pain and reduction of opioid dose following laparoscopic tubal ligation; as an adjunct anesthetic in ophthalmic surgery; treatment of shivering; premedication to attenuate the cardiostimulatory and postanesthetic delirium of ketamine; use in children",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F158379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Precedex&reg; may be confused with Peridex&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Errors have occurred due to misinterpretation of dosing information; use caution. Maintenance dose expressed as mcg/kg/",
"       <b>",
"        hour",
"       </b>",
"       .",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F158369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypotension (24% to 54%), bradycardia (5% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Respiratory depression (37%; placebo 32%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Atrial fibrillation (4% to 5%), hypovolemia (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypocalcemia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (3% to 9%),  xerostomia (3% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Urine output decreased (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pleural effusion (2%), wheezing (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Abdominal pain, abnormal vision, acidosis, agitation, alkaline phosphatase increased, ALT increased, anemia, apnea, arrhythmia, AST increased, atrioventricular block, BUN increased, bronchospasm, cardiac arrest, confusion, delirium, diaphoresis, diarrhea, dizziness, dyspnea, extrasystoles, fever, GGT increased, hallucination, headache, heart block, hemorrhage, hepatic impairment, hyperbilirubinemia, hypercapnia, hyperkalemia, hypertension, hypoglycemia, hypoventilation, hypoxia, illusion, MI, neuralgia, neuritis, oliguria, pain, photopsia, pulmonary congestion, respiratory acidosis, rigors, seizure, speech disorder, supraventricular tachycardia, tachycardia, thirst, T-wave inversion, ventricular arrhythmia, ventricular tachycardia, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F158341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed in the manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F158325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular effects: Episodes of bradycardia, hypotension, and sinus arrest have been associated with rapid I.V. administration (eg, bolus administration) or when given to patients with high vagal tone. When used for ICU sedation, use of a loading dose is optional; for the maintenance infusion, titration no more frequently than every 30 minutes may reduce the incidence of hypotension (Gerlach, 2009). If medical intervention is required, treatment may include stopping or decreasing the infusion, increasing the rate of I.V. fluid administration, use of pressor agents, and elevation of the lower extremities.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Transient hypertension: Has been primarily observed during loading dose administration and is associated with the initial peripheral vasoconstrictive effects of dexmedetomidine. Treatment of this is generally unnecessary; however, reduction of infusion rate may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with heart block, bradycardia, severe ventricular dysfunction, hypovolemia, or chronic hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; cardiovascular adverse events (eg, bradycardia, hypotension) may be more pronounced.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; dosage reductions recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vasodilators: Use with caution in patients receiving vasodilators or drugs which decrease heart rate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; cardiovascular events (eg, bradycardia, hypotension) may be more pronounced. Dose reduction may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Arousability: Patients may be arousable and alert when stimulated. This alone should not be considered as lack of efficacy in the absence of other clinical signs/symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced personnel: Should be administered only by persons skilled in management of patients in intensive care setting or operating room. Patients should be continuously monitored.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: When withdrawn abruptly in patients who have received &gt;24 hours, withdrawal symptoms similar to clonidine withdrawal may result (eg, hypertension, nervousness, agitation, headaches). Use for &gt;24 hours is not recommended by the manufacturer.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F158366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2A6 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2C9 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F158330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Alpha2-Antagonist): May diminish the antihypertensive effect of Alpha2-Agonists. Management: Consider avoiding concurrent use.  If these combinations cannot be avoided, monitor for decreased effects of alpha2-agonists if an alpha2-antagonist is initiated/dose increased, or increased effects if an alpha2-antagonist is discontinued/dose decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Alpha2-Agonists may enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the alpha",
"     <sub>",
"      2",
"     </sub>",
"     -agonist is abruptly withdrawn.  Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2A6 Inhibitors (Moderate): May decrease the metabolism of CYP2A6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2A6 Inhibitors (Strong): May decrease the metabolism of CYP2A6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Alpha2-Agonists may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May diminish the antihypertensive effect of Alpha2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May diminish the antihypertensive effect of Alpha2-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F158332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6826804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. There are no adequate and well-controlled studies in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F158362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Precedex Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mcg/mL (2 mL): $95.11",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F158334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Level of sedation; heart rate, respiration, rhythm, blood pressure; pain control",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Critically-ill mechanically ventilated patients: Monitor depth of sedation with either the Richmond Agitation-Sedation Scale (RASS) or Sedation-Agitation Scale (SAS) (Barr, 2013)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F158343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Precedex (AR, AU, BR, CZ, HK, ID, KP, MX, MY, NZ, PE, PH, PL, SG, TH, TW, UY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F158324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Selective alpha",
"     <sub>",
"      2",
"     </sub>",
"     -adrenoceptor agonist with anesthetic and sedative properties thought to be due to activation of G-proteins by alpha",
"     <sub>",
"      2a",
"     </sub>",
"     -adrenoceptors in the brainstem resulting in inhibition of norepinephrine release; peripheral alpha",
"     <sub>",
"      2b",
"     </sub>",
"     -adrenoceptors are activated at high doses or with rapid I.V. administration resulting in vasoconstriction.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F158340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: I.V. Bolus: 5-10 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: 15-30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration (dose dependent): 60-120 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      ss",
"     </sub>",
"     : ~118 L; rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~94%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via N-glucuronidation, N-methylation,  and CYP2A6",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Distribution: ~6 minutes; Terminal: ~up to 3 hours (Venn, 2002); significantly prolonged in patients with severe hepatic impairment (Cunningham, 1999)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (95%); feces (4%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Arain SR and Ebert TJ, &ldquo;The Efficacy, Side Effects, and Recovery Characteristics of Dexmedetomidine Versus Propofol When Used for Intraoperative Sedation,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2002, 95(2):461-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/53/33622/abstract-text/12145072/pubmed\" id=\"12145072\" target=\"_blank\">",
"        12145072",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Baddigam K, Russo P, Russo J, et al, &ldquo;Dexmedetomidine in the Treatment of Withdrawal Syndromes in Cardiothoracic Surgery Patients,&rdquo;",
"      <i>",
"       J Intensive Care Med",
"      </i>",
"      , 2005, 20(2):118-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/53/33622/abstract-text/15855224/pubmed\" id=\"15855224\" target=\"_blank\">",
"        15855224",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Barr J, Fraser GL, Puntillo K, et al, &ldquo;Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in Adult Patients in the Intensive Care Unit,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2013, 41(1):263-306.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/53/33622/abstract-text/23269131/pubmed\" id=\"23269131\" target=\"_blank\">",
"        23269131",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Belleville JP, Ward DS, Bloor BC, et al, &ldquo;Effects of Intravenous Dexmedetomidine in Humans I. Sedation, Ventilation, and Metabolic Rate,&rdquo;",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 1992, 77(6):1125-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/53/33622/abstract-text/1361310/pubmed\" id=\"1361310\" target=\"_blank\">",
"        1361310",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Berkenbosch JW, Wankum PC, and Tobias JD, &ldquo;Prospective Evaluation of Dexmedetomidine for Noninvasive Procedural Sedation in Children,&rdquo;",
"      <i>",
"       Pediatr Crit Care Med",
"      </i>",
"      , 2005, 6(4):435-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/53/33622/abstract-text/15982430/pubmed\" id=\"15982430\" target=\"_blank\">",
"        15982430",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cunningham FE, Baughman VL, Tonkovich L, et al, &ldquo;Pharmacokinetics of Dexmedetomidine (DEX) in Patients With Hepatic Failure (HF),&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1999, 65:128.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Rhodes A, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2013, 41(2):580-637.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/53/33622/abstract-text/23353941/pubmed\" id=\"23353941\" target=\"_blank\">",
"        23353941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gerlach AT and Dasta JF, &ldquo;Dexmedetomidine: An Updated Review,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2007, 41(2):245-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/53/33622/abstract-text/17299013/pubmed\" id=\"17299013\" target=\"_blank\">",
"        17299013",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gerlach AT, Dasta JF, Steinberg S, et al, &ldquo;A New Dosing Protocol Reduces Dexmedetomidine-Associated Hypotension in Critically Ill Surgical Patients,&rdquo;",
"      <i>",
"       J Crit Care",
"      </i>",
"      , 2009, 24(4):568-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/53/33622/abstract-text/19682844/pubmed\" id=\"19682844\" target=\"_blank\">",
"        19682844",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ickeringill M, Shehabi Y, Adamson H, et al, &ldquo;Dexmedetomidine Infusion Without Loading Dose in Surgical Patients Requiring Mechanical Ventilation: Haemodynamic Effects and Efficacy,&rdquo;",
"      <i>",
"       Anaesth Intensive Care",
"      </i>",
"      , 2004, 32(6):741-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/53/33622/abstract-text/15648981/pubmed\" id=\"15648981\" target=\"_blank\">",
"        15648981",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pandharipande PP, Pun BT, Herr DL, et al, &ldquo;Effect of Sedation With Dexmedetomidine vs Lorazepam on Acute Brain Dysfunction in Mechanically Ventilated Patients. The MENDS Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2007, 298(22):2644-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/53/33622/abstract-text/18073360/pubmed\" id=\"18073360\" target=\"_blank\">",
"        18073360",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Phan H and Nahata MC, &ldquo;Clinical Uses of Dexmedetomidine in Pediatric Patients,&rdquo;",
"      <i>",
"       Paediatr Drugs",
"      </i>",
"      , 2008, 10(1):49-69.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/53/33622/abstract-text/18162008/pubmed\" id=\"18162008\" target=\"_blank\">",
"        18162008",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Riker RR, Shehabi Y, Bokesch PM, et al, &ldquo;Dexmedetomidine vs Midazolam for Sedation of Critically Ill Patients. A Randomized Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2009, 301(5):489-99.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/53/33622/abstract-text/19188334/pubmed\" id=\"19188334\" target=\"_blank\">",
"        19188334",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shehabi Y, Ruettimann U, Adamson H, et al, &ldquo;Dexmedetomidine Infusion for More Than 24 Hours in Critically Ill Patients: Sedative and Cardiovascular Effects,&rdquo;",
"      <i>",
"       Intensive Care Med",
"      </i>",
"      , 2004, 30(12):2188-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/53/33622/abstract-text/15338124/pubmed\" id=\"15338124\" target=\"_blank\">",
"        15338124",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Venn M, Newman J, and Grounds M, &ldquo;A Phase II Study To Evaluate the Efficacy of Dexmedetomidine for Sedation in the Medical Intensive Care Unit,&rdquo;",
"      <i>",
"       Intensive Care Med",
"      </i>",
"      , 2003, 29(2):201-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/53/33622/abstract-text/12594584/pubmed\" id=\"12594584\" target=\"_blank\">",
"        12594584",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8897 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-7ADB670DEC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_53_33622=[""].join("\n");
var outline_f32_53_33622=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158352\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158353\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158371\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158356\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158357\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158358\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158359\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158336\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158321\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158338\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14471305\">",
"      Usual Infusion Concentrations: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14471306\">",
"      Usual Infusion Concentrations: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158377\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158337\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158368\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158379\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158369\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158341\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158325\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158366\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158330\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158332\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6826804\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158362\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323099\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158334\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158343\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158324\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158340\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8897\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8897|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?33/52/34627?source=related_link\">",
"      Dexmedetomidine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/6/37989?source=related_link\">",
"      Dexmedetomidine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_53_33623="Keloid ear lobe";
var content_f32_53_33623=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F54044&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F54044&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Keloid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A large keloid of the ear lobe.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_53_33623=[""].join("\n");
var outline_f32_53_33623=null;
var title_f32_53_33624="Tumor necrosis factor-alpha inhibitors: Risk of malignancy";
var content_f32_53_33624=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Tumor necrosis factor-alpha inhibitors: Risk of malignancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/53/33624/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/53/33624/contributors\">",
"     John H Stone, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/53/33624/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/53/33624/contributors\">",
"     Daniel E Furst, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/53/33624/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/53/33624/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/53/33624/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 23, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhibitors of tumor necrosis factor (TNF)-alpha represent important treatment advances for a number of inflammatory conditions, including rheumatoid arthritis, the seronegative spondyloarthropathies, and inflammatory bowel disease. TNF-alpha inhibitors offer a targeted strategy that contrasts with the nonspecific immunosuppressive agents traditionally used to treat most inflammatory diseases.",
"   </p>",
"   <p>",
"    However, multiple adverse effects of TNF-alpha inhibition have been identified through both clinical trials and postmarketing surveillance. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Malignancy",
"     </li>",
"     <li>",
"      Injection site reactions",
"     </li>",
"     <li>",
"      Infusion reactions",
"     </li>",
"     <li>",
"      Demyelinating disease",
"     </li>",
"     <li>",
"      Heart failure",
"     </li>",
"     <li>",
"      Induction of autoimmunity",
"     </li>",
"     <li>",
"      Infections",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk of malignancy associated with targeted TNF-alpha inhibitor use will be reviewed here. Problems associated with the injection reactions, infusion reactions, demyelinating disease, heart failure, and infections (including tuberculosis) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/55/40825?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/4/2120?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: Induction of antibodies, autoantibodies, and autoimmune diseases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/49/32538?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: Risk of bacterial, viral, and fungal infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/38/24169?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors and mycobacterial infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;TNF-alpha inhibitors are associated with potentially serious adverse effects. However, these risks must be interpreted in the context of the potential benefits associated with these medications, as well as in the context of the adverse effects associated with conventional treatments for immune-mediated diseases. The adverse effects of conventional treatments, including the risk of malignancy induction, are also significant in many cases. Thus, the decision to use a TNF-alpha inhibitor must be an individual one, based upon the specific clinical features and the unique risk profile of a given patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Inhibitors of TNF-alpha",
"    </span>",
"    &nbsp;&mdash;&nbsp;Five inhibitors of TNF-alpha are approved by the United States Food and Drug Administration (FDA) for the treatment of rheumatoid arthritis (RA), Crohn&rsquo;s disease, and selected other inflammatory disorders. These medications are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"       Etanercept",
"      </a>",
"      &mdash; A soluble TNF-alpha receptor fusion protein",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"       Infliximab",
"      </a>",
"      &mdash; A chimeric",
"      <span class=\"nowrap\">",
"       (mouse/human)",
"      </span>",
"      anti-TNF-alpha antibody",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"       Adalimumab",
"      </a>",
"      &mdash; A fully human monoclonal anti-TNF-alpha antibody",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/6/39014?source=see_link\">",
"       Certolizumab pegol",
"      </a>",
"      &mdash; An antigen-binding fragment (Fab&rsquo;) of a humanized monoclonal antibody coupled to polyethylene glycol",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/24/35206?source=see_link\">",
"       Golimumab",
"      </a>",
"      &mdash; A human anti-TNF-alpha monoclonal antibody",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     Etanercept",
"    </a>",
"    is a soluble, bivalent TNF-alpha receptor.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     Infliximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/24/35206?source=see_link\">",
"     golimumab",
"    </a>",
"    are monoclonal antibodies. In contrast to infliximab, adalimumab, and golimumab, certolizumab does not contain an Fc portion and, therefore, does not induce complement activation, antibody-dependent cellular cytotoxicity, or apoptosis. The full impact of this structural change on the efficacy or safety of the agent is not clear. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/19/3384?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of biologic agents in the rheumatic diseases\", section on 'TNF inhibition'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/2/33829?source=see_link\">",
"     \"Certolizumab pegol for treatment of Crohn's disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     TNF-alpha biology",
"    </span>",
"    &nbsp;&mdash;&nbsp;TNF-alpha, originally known as cachexin, was recognized in 1975 for its ability to lyse tumors in a variety of in vitro and mouse models (hence, the name &ldquo;tumor necrosis factor&rdquo;) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33624/abstract/1\">",
"     1",
"    </a>",
"    ]. The biology of TNF-alpha is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/55/40825?source=see_link&amp;anchor=H3#H3\">",
"     \"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects\", section on 'TNF-alpha biology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The activity of TNF-alpha against tumors in laboratory models and, potentially, in humans raises the possibility that TNF-alpha inhibition might potentiate the clinical risk of malignancy. However, a significant body of literature also supports the concept that TNF-alpha is active against some forms of cancer. Experimental evidence of an anti-tumor effect for TNF-alpha led to the systemic administration of this cytokine for the treatment of some malignancies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/28/27081?source=see_link\">",
"     \"Cutaneous melanoma: Management of in transit metastases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/47/38650?source=see_link\">",
"     \"Local treatment for primary soft tissue sarcoma of the extremities and chest wall\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Standardized incidence ratios",
"    </span>",
"    &nbsp;&mdash;&nbsp;In formal analyses of the risk of malignancy posed by TNF-alpha inhibitor use, standardized incidence ratios (SIRs) have been used to assess the degree of risk among patients receiving TNF inhibitors compared with the baseline risk of malignancy in the general population.",
"   </p>",
"   <p>",
"    SIR is defined in the following manner:",
"   </p>",
"   <p>",
"    SIR = (Observed cases of malignancy &divide; Expected cases) x 100",
"   </p>",
"   <p>",
"    In order to estimate the number of expected cases of malignancy within a population over a specific period of time, investigators often refer to the Surveillance, Epidemiology, and End Results (SEER) database, a population-based registry that includes all invasive cancers plus cancer of the urinary bladder and breast carcinoma in situ [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33624/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CHALLENGES IN ESTABLISHING MALIGNANCY RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proof of a link between TNF-alpha inhibitor use and the development of cancer is difficult for several reasons. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Risk from underlying disease &mdash; Patients treated with TNF-alpha inhibitors may have an inherent predisposition to cancer based upon their underlying disease. As examples, patients with RA may have up to a 10 to 15 percent overall increase in the risk of cancer compared with the general population, and patients with ulcerative colitis have an increased risk of colon cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/53/33624/abstract/3-6\">",
"       3-6",
"      </a>",
"      ]. The risk of malignancy is site-specific in RA, in which it appears to be increased for lymphoma and, perhaps, for lung cancer but in which it appears to be potentially decreased for colorectal and breast cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/53/33624/abstract/7\">",
"       7",
"      </a>",
"      ]. It can be difficult to distinguish the additional risk conferred by TNF-alpha inhibitors from the baseline risk.",
"     </li>",
"     <li>",
"      Risk from other medications &mdash; Patients with immune-mediated disorders often receive other medications concomitantly with TNF-alpha inhibitors that increase the risk of cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/53/33624/abstract/8-10\">",
"       8-10",
"      </a>",
"      ]. As an example,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (MTX), commonly used with TNF-alpha inhibitors in the treatment of RA, is associated with an elevated risk of lymphoma in some but not all studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/53/33624/abstract/8,11,12\">",
"       8,11,12",
"      </a>",
"      ]. Similar considerations apply for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"       chlorambucil",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      , and other conventional immunosuppressive medications. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11223?source=see_link&amp;anchor=H6#H6\">",
"       \"Major side effects of low-dose methotrexate\", section on 'Common toxicities'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/32/25098?source=see_link\">",
"       \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Exclusion of cancer patients from clinical trials &mdash; Patients with prior malignancy have been excluded from clinical trials with TNF inhibitors because of concern over a potentially increased risk of recurrent or new malignancy in such patients. Thus, data regarding cancer risk in this population of particular interest are limited. (See",
"      <a class=\"local\" href=\"#H24092381\">",
"       'Cancer risk in patients with prior malignancy'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     GENERAL STUDIES OF CANCER RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is evidence both for and against increased overall cancer risk with use of TNF inhibitors, and study design can influence the findings. Rigorous clinical trials have been performed for the TNF-alpha inhibitors, in contrast to most nonbiologic disease-modifying antirheumatic drugs (DMARDs), facilitating detection of events that occur during the trial period. Long-term risks of cancer, however, cannot be determined from short-term randomized trials.",
"   </p>",
"   <p>",
"    Although some meta-analyses of clinical trial data have found increased cancer risk with TNF inhibitor use, observational data, particularly from registries, have generally been unable to confirm these findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33624/abstract/3,12-18\">",
"     3,12-18",
"    </a>",
"    ]. This discrepancy may result, in part, from the more complete reporting of malignancies in clinical trials than in the context of routine practice, in which, in the absence of a registry, reporting may depend upon voluntary postmarketing surveillance. Evaluation of risk using observational studies is also highly dependent upon how cancers are identified and upon what comparator is chosen.",
"   </p>",
"   <p>",
"    The following provide examples of the available evidence:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Evidence of increased risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial concern regarding a possible association between TNF-alpha inhibitor use and cancer arose from postmarketing reports to the US Food and Drug Administration (FDA) of 26 cases of lymphoma (mostly non-Hodgkin lymphoma) among patients with rheumatoid arthritis (RA) or Crohn&rsquo;s disease treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33624/abstract/19\">",
"     19",
"    </a>",
"    ]. Two patients had regression of their lymphoma when anti-TNF-alpha therapy was discontinued. Further postmarketing reports to the FDA raised concerns regarding increased risk of malignancy with use of these drugs in children and adolescents who received anti-TNF-alpha therapy for juvenile idiopathic arthritis (JIA) or for inflammatory bowel disease (IBD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33624/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An FDA analysis identified 48 cases over a 10-year period (1998 to 2008) of malignancies in these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33624/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Approximately half of these cases were Hodgkin and non-Hodgkin lymphomas, including 10 cases of hepatosplenic T-cell lymphoma in patients with IBD who had also received 6-mercaptopurine or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ; others included leukemia, melanoma, and solid organ cancers. Warnings about the use of TNF inhibitors in children and adolescents were issued based upon this analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33624/abstract/22\">",
"     22",
"    </a>",
"    ]. Warnings were also issued describing cases of leukemia in adults, as well as in adolescents and children.",
"   </p>",
"   <p>",
"    Other reports addressed the potential relationships between TNF-alpha inhibitors and other types of cancer, particularly solid malignancies and skin cancer.",
"   </p>",
"   <p>",
"    The potential relationship between TNF inhibitor use and the development of solid malignancies was addressed in a meta-analysis, which included data from nine clinical trials involving 3493 patients who received TNF inhibitors and 1512 patients who received placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33624/abstract/13\">",
"     13",
"    </a>",
"    ]. The following observations were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The pooled odds ratio (OR) for all malignancies among patients treated with TNF inhibitors was 3.3 (95% CI 1.2-9.1).",
"     </li>",
"     <li>",
"      Malignancies were significantly more common in patients treated with higher doses compared with patients who received lower doses of anti-TNF antibodies.",
"     </li>",
"     <li>",
"      Among the 26 malignancies observed in the TNF inhibitor group, there were 15 solid malignancies. In contrast, only one solid malignancy was observed among patients in the comparison group.",
"     </li>",
"     <li>",
"      For patients treated with anti-TNF antibodies, the number needed to induce one additional malignancy of any type within a treatment period of 6 to 12 months was 154 (95% CI 91-500).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Evidence of no increased long-term risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some evidence indicates that overall cancer risk may not increase over time in patients who use TNF inhibitors for RA rather than other therapies, although a small increase in skin cancers has been noted. Several reports have shown that risk is elevated only for skin cancer but not for other cancers overall, compared with patients receiving other disease-modifying antirheumatic drugs (DMARDs) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33624/abstract/15-18\">",
"     15-18",
"    </a>",
"    ]. In addition, a meta-analysis of six randomized trials involving 3419 patients, in which DMARD-na&iuml;ve patients with RA were treated either with a TNF inhibitor or with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , found no significant difference in the rate of malignancies between the two groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33624/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Skin cancer risk'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The following observations were made using population-based registry data from Sweden [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33624/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was no overall elevation of cancer risk during 25,693 person-years of follow-up in 6366 patients newly started on TNF inhibitors compared with the biologics-naive RA cohort of 61,160 patients (relative risk 1.0, 95% CI 0.86-1.15). Similarly, there was no elevation in risk compared with patients who were starting",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      or nonbiologic DMARD combinations.",
"     </li>",
"     <li>",
"      Neither the incidence nor the relative risk of cancer increased with time after starting TNF inhibitor therapy or with cumulative duration of treatment.",
"     </li>",
"     <li>",
"      There were statistically significant differences in cancer risks between",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      during the first year following the start of treatment, but these differences subsequently disappeared.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further evidence that neither TNF inhibitors nor other biologic agents pose a significantly increased overall risk of malignancy comes from a 2012 meta-analysis of 63 randomized trials involving 29,423 patients, which compared patients treated for RA with TNF inhibitors or other biologic agents (either alone or in combination with nonbiologic DMARDs) with controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33624/abstract/24\">",
"     24",
"    </a>",
"    ]. The study found no increase in the rate of malignancy in trials of at least 24 weeks&rsquo; duration in patients receiving biologic agents overall or with any individual biologic agent, including TNF inhibitors,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/14/18662?source=see_link\">",
"     abatacept",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"     tocilizumab",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/294?source=see_link\">",
"     anakinra",
"    </a>",
"    , except in one subset. There was a small increased risk at 52 weeks for patients receiving a TNF inhibitor plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (OR 2.1, 95% CI 1.1-3.9; absolute risk of 1.1 versus 0.5 percent), but differences between groups were not statistically significant with other analyses, with other time points, or with TNF inhibitor monotherapy. Thus, the importance of this finding is uncertain. A total of only 211 malignancies were observed during the 63 trials. Despite this evidence suggesting no increase in malignancy risk overall, risks may be increased for certain individual malignancies. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Studies suggesting increased lymphoma risk'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H13\">",
"     'Solid malignancy risk'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H16\">",
"     'Skin cancer risk'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     LYMPHOMA RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data related to the risk of lymphoma associated with the use of targeted TNF inhibitors are conflicting. The following studies illustrate the range of findings:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Studies suggesting increased lymphoma risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data presented to an advisory meeting of the FDA in 2003 included 70 cases of lymphoma among approximately 140,000 patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33624/abstract/25\">",
"     25",
"    </a>",
"    ]. Data on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    were also reviewed, although the clinical experience with these drugs was significantly smaller than with etanercept at that time. The following estimates were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      SIR for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      &mdash; 2.3 to 3.5",
"     </li>",
"     <li>",
"      SIR for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      &mdash; 6.4",
"     </li>",
"     <li>",
"      SIR for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      &mdash; 5.5",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The SIR of lymphoma among patients with RA in general, excluding those treated with TNF inhibitors, was estimated to be 2.",
"   </p>",
"   <p>",
"    Two subsequent major studies also found an increased risk of lymphoma among RA patients treated with TNF inhibitors. The South Swedish Arthritis Treatment Group (SSATG) registry includes more than 90 percent of RA patients treated with TNF inhibitors in that region [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33624/abstract/26\">",
"     26",
"    </a>",
"    ]. From this registry, 757 patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    were identified. A comparison group of 800 RA patients treated with conventional DMARDs was drawn from a community-based cohort. In another study, the risk of lymphoma in patients with RA was increased only in those with a high level of disease activity compared with other RA patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33624/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the SIR for all types of malignancy was not different between the two groups, there was an increased relative risk of lymphoma among patients treated with TNF inhibitors, as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the TNF inhibitor group, 16 tumors (five lymphomas) were identified over 1603 patient-years at risk. In the DMARD group, 69 tumors (two lymphomas) were identified over 3948 patient-years.",
"     </li>",
"     <li>",
"      The SIR for development of any type of malignancy in the TNF inhibitor group was 1.1 (95% CI 0.6-1.8), compared with 1.4 (95% CI 1.1-1.8) for the DMARD group.",
"     </li>",
"     <li>",
"      The relative risk of lymphoma in the TNF inhibitor group was 11.5 (95% CI 3.7-26.9), compared with 1.3 (95% CI 0.2-4.5) for the DMARD group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The small number of malignancies detected within this and most individual clinical trials or registries was addressed in the meta-analysis of trials involving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    described above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33624/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Evidence of increased risk'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"       Infliximab",
"      </a>",
"      drug label warning &mdash; In October 2004, the FDA and the manufacturer of infliximab in the United States added a boxed warning about the risk of lymphoma to the labeling of this agent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/53/33624/abstract/28\">",
"       28",
"      </a>",
"      ]. Similarly, in July 2006, the manufacturers of infliximab in Canada issued a further letter to Canadian healthcare professionals regarding reports to the FDA of six cases of hepatosplenic T-cell lymphoma (HSTCL), a rare form of non-Hodgkin lymphoma. The letter noted that reports of HSTCL occurring in Crohn&rsquo;s disease patients receiving these drugs without infliximab have also been published. As of the end of 2010, a total of 20 cases of HSTCL associated with infliximab had been identified by the FDA. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Evidence of increased risk'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Studies suggesting no increased lymphoma risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other studies have failed to confirm an increased risk of lymphoma among patients treated with TNF inhibitors.",
"   </p>",
"   <p>",
"    A population-based study from Sweden was performed on patients with RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33624/abstract/14\">",
"     14",
"    </a>",
"    ]. The study included a prevalent cohort (n = 53,067), an incident cohort (n = 3703), and a cohort treated with TNF inhibitors (n = 4160). Data from all three cohorts were linked to the Swedish Cancer Register to ensure completeness in reporting. The study included almost 500 observed hematopoietic malignancies.",
"   </p>",
"   <p>",
"    The following findings were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prevalent and incident patients with RA were at increased risk for lymphoma (SIR of 1.9 and 2, respectively) and leukemia (SIR of 2.1 and 2.2, respectively) compared with the general population.",
"     </li>",
"     <li>",
"      RA patients treated with TNF inhibitors were at increased risk of lymphoma compared with the general population (SIR of 2.9). However, after adjustment for age, sex, and disease duration, the risk of lymphoma among patients in the cohort treated with TNF inhibitors was NOT higher than that among RA patients not treated with TNF inhibitors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further support for a lack of lymphoma risk associated with TNF inhibitors comes from a National Data Bank for Rheumatic Diseases longitudinal study in the United States of long-term outcomes in RA in which patients completed questionnaires every six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33624/abstract/12\">",
"     12",
"    </a>",
"    ]. The study included 19,591 participants and a total of 89,710 patient-years of follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33624/abstract/12\">",
"     12",
"    </a>",
"    ]. Fifty-five percent of the patients received TNF inhibitors, and 68 percent received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX) during the period of observation.",
"   </p>",
"   <p>",
"    The following findings were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence rate of lymphoma for the overall cohort was 106 per 100,000 person-years of exposure (95% CI 87-130).",
"     </li>",
"     <li>",
"      The SIR for lymphoma was 1.8 (95% CI 1.5 to 2.2) among patients in this cohort compared with the SEER database of individuals in the general population [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/53/33624/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The odds ratio for lymphoma among RA patients who received a TNF inhibitor compared with RA patients who did not receive anti-TNF therapy was 1.0 (95% CI 0.6-1.8).",
"     </li>",
"     <li>",
"      The odds ratio for lymphoma in patients who received a TNF inhibitor plus MTX compared with patients who received MTX alone was 1.1 (95% CI 0.6-2).",
"     </li>",
"     <li>",
"      When considered individually, neither",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      nor",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      was associated with an increased risk of lymphoma.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a registry-based case-control study from France, 38 cases of lymphoma in patients with rheumatic diseases treated with TNF inhibitors were analyzed with 74 lymphoma-free control cases also receiving a TNF inhibitor, using the French population as a reference [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33624/abstract/29\">",
"     29",
"    </a>",
"    ]. There was an increased risk of lymphoma in those treated with an anti-TNF compared with the general population (SIR of 2.4, 95% CI 1.7-3.2); however, this increased risk was similar to that seen in patients with comparably severe rheumatic inflammatory diseases not treated with TNF inhibitors. There was a trend for greater risk of lymphoma with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    than with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    . However, the few cases and short observation period suggest that larger and longer studies are needed.",
"   </p>",
"   <p>",
"    A systematic review and meta-analysis of registry data and of prospective observational studies was also unable to demonstrate a statistically significant increase in lymphoma rates in pooled data from three registries that each included more than 4000 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33624/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SOLID MALIGNANCY RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data on the risk of solid malignancy as a complication of TNF inhibitor use are also mixed. However, there is particular concern about the possibility of a synergistic increase in the risk of solid malignancies when TNF inhibitors are used in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33624/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Cyclophosphamide and TNF inhibitor combination'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The potential relationship between TNF inhibitor use and increased risk for the development of solid malignancies was addressed in the clinical trials meta-analysis described above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33624/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Evidence of increased risk'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In contrast, the Swedish Early Arthritis Registry cited above concluded that the risk of solid malignancies among patients treated with TNF inhibitors is not higher than one would expect from the underlying disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33624/abstract/31\">",
"     31",
"    </a>",
"    ]. This was a population-based study comprised of a prevalent RA cohort (n = 53,067), an incident cohort (n = 3703), and a cohort of patients treated with TNF inhibitors (n = 4160). Data from all three cohorts were linked to the Swedish Cancer Register to ensure completeness in reporting. The risk of solid malignancies in this cohort was not greater than that of the general population in Sweden (SIR of 0.9; 95% CI 0.7-1.2).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Cyclophosphamide and TNF inhibitor combination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Wegener&rsquo;s Granulomatosis",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     Etanercept",
"    </a>",
"    Trial (WGET) was a randomized, double-blind comparison of etanercept versus placebo added to standard of care for the maintenance of remission in 180 patients with granulomatosis with polyangiitis (Wegener&rsquo;s) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33624/abstract/32\">",
"     32",
"    </a>",
"    ]. Median follow-up was just over two years. The following findings were noted with respect to malignancy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Six of the 89 patients (7 percent) assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      developed solid malignancies compared with no solid malignancies in the standard therapy group. During the six-month observation period that followed the discontinuation of experimental treatment, two additional solid malignancies were diagnosed in patients who had received a TNF inhibitor, and one was observed in a patient who had not been treated with TNF inhibition.",
"     </li>",
"     <li>",
"      All six of the patients with solid malignancies detected during the trial and seven of the nine patients overall were also treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      during the trial.",
"     </li>",
"     <li>",
"      Based upon the age- and sex-specific incidence rate for solid malignancies in the SEER database, 1.9 solid malignancies would have been expected in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      group. Thus, the SIR for solid malignancies among patients treated with the combination of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      and etanercept during the trial was 3.1 (95% CI 1.2-6.8).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the overall number of malignancies observed was small, the surprisingly high number of solid malignancies observed over a period of only two years suggests that the combination of TNF inhibition and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    heightens the risk of cancer beyond the risk observed with cyclophosphamide alone. Because of this, we recommend not using TNF inhibitors together with cyclophosphamide. Additional studies are required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Etanercept label warning",
"    </span>",
"    &nbsp;&mdash;&nbsp;The drug label for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    bears the following warning regarding a potential drug interaction with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    : &ldquo;May increase the risk of noncutaneous solid malignancy when used with cyclophosphamide. Concurrent therapy is not recommended.&rdquo;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SKIN CANCER RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence of an increased risk of nonmelanoma skin cancer among patients treated with TNF inhibitors includes meta-analyses of data from registries, from prospective observational studies, and from randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33624/abstract/15,16,33,34\">",
"     15,16,33,34",
"    </a>",
"    ]. More limited studies have suggested an increased risk of melanoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33624/abstract/15,33\">",
"     15,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The range of evidence is demonstrated by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a systematic review and meta-analysis of data from four observational studies involving over 28,000 patients, the risk of nonmelanoma skin cancer was significantly increased among patients exposed to TNF inhibitors compared with those who were not (relative risk [RR] 1.45, 95% CI 1.15-1.76) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/53/33624/abstract/15\">",
"       15",
"      </a>",
"      ]. A pooled analysis of two studies identified in the review that reported data for melanoma found a trend suggesting an increased risk of melanoma, but the data were imprecise and did not achieve statistical significance (RR 1.79, 95% CI 0.92-2.67).",
"     </li>",
"     <li>",
"      The risk of nonmelanoma skin cancer was significantly increased in patients treated with TNF inhibitors among a cohort of 20,648 patients with RA followed in the national administrative databases of the US Department of Veterans&rsquo; Affairs, compared with patients who had received nonbiologic DMARDs (18.9 versus 12.7 per 1000 patient-years; hazard ratio 1.42, 95% CI 1.24-1.63) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/53/33624/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A meta-analysis of patient-level data from randomized trials of TNF inhibitor therapy, involving 15,418 patients, showed a significantly increased risk of nonmelanoma skin cancer among patients receiving TNF inhibitors (RR 2.02, 95% CI 1.11-3.95) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/53/33624/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24092381\">",
"    <span class=\"h1\">",
"     CANCER RISK IN PATIENTS WITH PRIOR MALIGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited study has failed to provide evidence for increased risk of recurrent or new cancer in patients treated with a TNF inhibitor who have a history of a prior malignancy. The paucity of data regarding this question has resulted from the exclusion of such patients from clinical trials with TNF inhibitors, because of concern over such risk, and from practice guidelines or drug labeling promoting caution in this population, given the lack of information to document safety. An analysis of data from the British Society for Rheumatology Biologics Register, which identified 293 patients with prior malignancy from among over 14,000 patients with rheumatoid arthritis (RA), failed to show an increased incidence of new malignancy in 177 patients who received a TNF inhibitor for treatment of active RA, compared with 117 patients who had received a traditional (nonbiologic) disease-modifying antirheumatic drug (DMARD) (25 versus 38 events per 1000 patient-years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33624/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The lack of evidence for an overall difference in risk of malignancy between the populations in the British Register study should be interpreted with caution, as undefined criteria used in practice by British rheumatologists for selecting therapy in such patients may have influenced the study outcomes. The study also found that, of patients with a history of melanoma, 3 of 17 treated with a TNF inhibitor but none of 10 treated with a nonbiologic DMARD experienced a recurrence of melanoma or a new malignancy. Whether melanoma conveys greater risk than other malignancies remains to be determined by further study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1942335\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data indicate that treatment with TNF inhibitors does not affect the prognosis of patients who develop cancer during or after treatment with these medications. An analysis of data from the Swedish clinical registries of rheumatoid arthritis (RA) patients, involving a total of 78,483 individuals, found that there were no differences between patients who had received TNF inhibitors and those who were na&iuml;ve to biologic disease-modifying antirheumatic drugs in the distributions of tumor stage or in the relative risk of death among patients diagnosed with cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33624/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The activity of tumor necrosis factor (TNF)-alpha against tumors in laboratory models and, potentially, in humans raises the possibility that inhibition of this cytokine may potentiate the clinical risk of malignancy. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'TNF-alpha biology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The decision to use a TNF inhibitor must be based upon the specific clinical features and unique risk profile of a given patient. The risks associated with TNF inhibitor use must be interpreted in the context of the potential benefits associated with these medications, as well as the adverse effects associated with conventional treatments for immune-mediated diseases. The adverse effects of conventional treatments, including the risk of malignancy induction, are also significant in many cases. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General issues'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical data on the risk of lymphomas, leukemias, and solid malignancies, as well as the overall risk of malignancy stemming from the use of TNF inhibitors, are mixed. The FDA has issued several warnings regarding such risk. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Evidence of increased risk'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Lymphoma risk'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Solid malignancy risk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Challenges in establishing the true magnitude of risk (if any) between TNF inhibitor use and the development of malignancy include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Increased predisposition to cancer based upon the patient&rsquo;s underlying disorder (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Challenges in establishing malignancy risk'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Concomitant use of other medications that can heighten malignancy risk, particularly",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      . We recommend not using TNF inhibitors together with cyclophosphamide (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Cyclophosphamide and TNF inhibitor combination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A lack of data from randomized trials to address risk of new or recurrent malignancy in patients with a prior history of cancer (see",
"      <a class=\"local\" href=\"#H24092381\">",
"       'Cancer risk in patients with prior malignancy'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risk of nonmelanoma skin cancer appears to be increased in patients who receive TNF inhibitors. The risk of melanoma is uncertain. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Skin cancer risk'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33624/abstract/1\">",
"      Carswell EA, Old LJ, Kassel RL, et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 1975; 72:3666.",
"     </a>",
"    </li>",
"    <li>",
"     National Cancer Institute: Surveillance Epidemiology and End Results Program. file://seer.cancer.gov/ (Accessed on January 22, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33624/abstract/3\">",
"      Askling J, van Vollenhoven RF, Granath F, et al. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment? Arthritis Rheum 2009; 60:3180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33624/abstract/4\">",
"      Georgescu L, Quinn GC, Schwartzman S, Paget SA. Lymphoma in patients with rheumatoid arthritis: association with the disease state or methotrexate treatment. Semin Arthritis Rheum 1997; 26:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33624/abstract/5\">",
"      Gridley G, McLaughlin JK, Ekbom A, et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993; 85:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33624/abstract/6\">",
"      Collins PD, Mpofu C, Watson AJ, Rhodes JM. Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst Rev 2006; :CD000279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33624/abstract/7\">",
"      Smitten AL, Simon TA, Hochberg MC, Suissa S. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther 2008; 10:R45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33624/abstract/8\">",
"      Symmons D. Excess mortality in rheumatoid arthritis--is it the disease or the drugs? J Rheumatol 1995; 22:2200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33624/abstract/9\">",
"      Cibere J, Sibley J, Haga M. Rheumatoid arthritis and the risk of malignancy. Arthritis Rheum 1997; 40:1580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33624/abstract/10\">",
"      Greenstein AJ, Mullin GE, Strauchen JA, et al. Lymphoma in inflammatory bowel disease. Cancer 1992; 69:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33624/abstract/11\">",
"      Ebeo CT, Girish MR, Byrd RP, et al. Methotrexate-induced pulmonary lymphoma. Chest 2003; 123:2150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33624/abstract/12\">",
"      Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 2007; 56:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33624/abstract/13\">",
"      Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295:2275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33624/abstract/14\">",
"      Askling J, Fored CM, Baecklund E, et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 2005; 64:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33624/abstract/15\">",
"      Mariette X, Matucci-Cerinic M, Pavelka K, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 2011; 70:1895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33624/abstract/16\">",
"      Askling J, Fahrbach K, Nordstrom B, et al. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf 2011; 20:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33624/abstract/17\">",
"      Dommasch ED, Abuabara K, Shin DB, et al. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol 2011; 64:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33624/abstract/18\">",
"      Thompson AE, Rieder SW, Pope JE. Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheum 2011; 63:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33624/abstract/19\">",
"      Brown SL, Greene MH, Gershon SK, et al. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002; 46:3151.",
"     </a>",
"    </li>",
"    <li>",
"     Early communication about an ongoing safety review of tumor necrosis factor (TNF) blockers (marketed as Remicade, Enbrel, Humira, and Cimzia). 6/4/2008 www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm070725.htm (Accessed on January 27, 2010).",
"    </li>",
"    <li>",
"     Follow-up to the June 4, 2008 early communication about the ongoing safety review of tumor necrosis factor (TNF) blockers (marketed as Remicade, Enbrel, Humira, Cimzia, and Simponi). August 4, 2009. www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm174449.htm (Accessed on January 27, 2010).",
"    </li>",
"    <li>",
"     Information for healthcare professionals: tumor necrosis factor (TNF) blockers (marketed as Remicade, Enbrel, Humira, Cimzia, and Simponi). FDA Alert (8/4/2009). www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm174474.htm (Accessed on January 27, 2010).",
"    </li>",
"    <li>",
"     Questions and answers - TNF blockers 8/25/2009. www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm180694.htm (Accessed on January 27, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33624/abstract/24\">",
"      Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA, et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA 2012; 308:898.",
"     </a>",
"    </li>",
"    <li>",
"     FDA Arthritis Advisory Committee Meeting, 3/04. file://www.fda.gov/ohrms/dockets/ac/cder03.html#Arthritis (Accessed on July 17, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33624/abstract/26\">",
"      Geborek P, Bladstr&ouml;m A, Turesson C, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005; 64:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33624/abstract/27\">",
"      Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006; 54:692.",
"     </a>",
"    </li>",
"    <li>",
"     Everitt, DE. Important drug warning. www.fda.gov/medwatch/SAFETY/2004/remicade_dearhcp.pdf (Accessed on January 18, 2004).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33624/abstract/29\">",
"      Mariette X, Tubach F, Bagheri H, et al. Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. Ann Rheum Dis 2010; 69:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33624/abstract/30\">",
"      Stone JH, Holbrook JT, Marriott MA, et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum 2006; 54:1608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33624/abstract/31\">",
"      Askling J, Fored CM, Brandt L, et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 2005; 64:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33624/abstract/32\">",
"      Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005; 352:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33624/abstract/33\">",
"      Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007; 56:2886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33624/abstract/34\">",
"      Amari W, Zeringue AL, McDonald JR, et al. Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis. Rheumatology (Oxford) 2011; 50:1431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33624/abstract/35\">",
"      Dixon WG, Watson KD, Lunt M, et al. Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register. Arthritis Care Res (Hoboken) 2010; 62:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33624/abstract/36\">",
"      Raaschou P, Simard JF, Neovius M, et al. Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents. Arthritis Rheum 2011; 63:1812.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7975 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-190.92.87.115-02329B04FB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_53_33624=[""].join("\n");
var outline_f32_53_33624=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Inhibitors of TNF-alpha",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TNF-alpha biology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Standardized incidence ratios",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CHALLENGES IN ESTABLISHING MALIGNANCY RISK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      GENERAL STUDIES OF CANCER RISK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Evidence of increased risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Evidence of no increased long-term risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      LYMPHOMA RISK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Studies suggesting increased lymphoma risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Studies suggesting no increased lymphoma risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SOLID MALIGNANCY RISK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Cyclophosphamide and TNF inhibitor combination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Etanercept label warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SKIN CANCER RISK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24092381\">",
"      CANCER RISK IN PATIENTS WITH PRIOR MALIGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1942335\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/2/33829?source=related_link\">",
"      Certolizumab pegol for treatment of Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/28/27081?source=related_link\">",
"      Cutaneous melanoma: Management of in transit metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/32/25098?source=related_link\">",
"      General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/47/38650?source=related_link\">",
"      Local treatment for primary soft tissue sarcoma of the extremities and chest wall",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11223?source=related_link\">",
"      Major side effects of low-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/19/3384?source=related_link\">",
"      Overview of biologic agents in the rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/38/24169?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors and mycobacterial infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/55/40825?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: An overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/4/2120?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: Induction of antibodies, autoantibodies, and autoimmune diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/49/32538?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: Risk of bacterial, viral, and fungal infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_53_33625="Unique aspects of anaphylaxis in infants";
var content_f32_53_33625=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Unique aspects of anaphylaxis in infants",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/53/33625/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/53/33625/contributors\">",
"     F Estelle R Simons, MD, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/53/33625/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/53/33625/contributors\">",
"     Robert A Wood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/53/33625/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/53/33625/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/53/33625/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H22500592\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rate of occurrence of anaphylaxis in infancy, defined here as birth through two years of age, is unknown but appears to be increasing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33625/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Anaphylaxis has been reported in infants as young as a few weeks of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33625/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. It can be fatal in infancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33625/abstract/7-9\">",
"     7-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other aspects of anaphylaxis are covered separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/54/40809?source=see_link\">",
"     \"Laboratory tests to support the clinical diagnosis of anaphylaxis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/0/38920?source=see_link\">",
"     \"Food-induced anaphylaxis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/13/1241?source=see_link\">",
"     \"Fatal anaphylaxis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/24/19847?source=see_link\">",
"     \"Biphasic and protracted anaphylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22500599\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis is based primarily upon a detailed history of the episode, including information about all exposures and events in the minutes to hours preceding the sudden onset of symptoms and signs. The clinical criteria for the diagnosis of anaphylaxis are similar in patients of all ages (",
"    <a class=\"graphic graphic_table graphicRef72225 \" href=\"mobipreview.htm?22/43/23228\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33625/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link&amp;anchor=H2#H2\">",
"     \"Anaphylaxis: Rapid recognition and treatment\", section on 'Definition and diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anaphylaxis can be difficult to recognize in infancy for a variety of reasons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33625/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is sometimes the first clinical manifestation of sensitization to an allergen. Caregivers might not realize what the symptoms and signs represent if they are unaware that the infant has been sensitized to this allergen.",
"     </li>",
"     <li>",
"      Itching, throat tightness, chest tightness, and other symptoms of anaphylaxis (",
"      <a class=\"graphic graphic_table graphicRef64957 \" href=\"mobipreview.htm?35/20/36172\">",
"       table 2",
"      </a>",
"      ) cannot be described by infants.",
"     </li>",
"     <li>",
"      Many of the signs of anaphylaxis are nonspecific, and are also seen in healthy infants for other reasons (eg, regurgitation or spitting up after feeding; flushing,",
"      <span class=\"nowrap\">",
"       hoarseness/dysphonia",
"      </span>",
"      after a crying spell; and loss of sphincter control, which is almost ubiquitous in this age group).",
"     </li>",
"     <li>",
"      Sometimes, the onset of an anaphylaxis episode in infancy is manifest only by sudden onset of lethargy or hypotonia, abrupt cessation of activity or play, or clinging to the caregiver.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a study of 605 children presenting to the ED with a food-related acute allergic reaction, the largest proportion of children with anaphylaxis were less than two years old. Many of these infants presented with hives and vomiting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33625/abstract/10\">",
"     10",
"    </a>",
"    ]. In this study, and in another large study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33625/abstract/5\">",
"     5",
"    </a>",
"    ], infants were less likely to have blood pressure documented during their emergency department stay than were older children.",
"   </p>",
"   <p>",
"    Tryptase measurements are less helpful in infants with anaphylaxis than in older patients. Tryptase levels are typically within normal limits in patients of all ages with anaphylaxis triggered by food and in those who remain normotensive. Food is by far the most common trigger of anaphylaxis in infancy. The normal range of serum tryptase levels in a pediatric population ranging in age from 6 months to 18 years is comparable to the normal range reported in the adult population; however, a normal range of serum tryptase levels has not been established for infants under the age of 6 months.",
"    <strong>",
"     In patients of any age, a tryptase level within the normal range does not rule out the clinical diagnosis of anaphylaxis",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33625/abstract/11,13-15\">",
"     11,13-15",
"    </a>",
"    ]",
"    <strong>",
"     .",
"    </strong>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/54/40809?source=see_link\">",
"     \"Laboratory tests to support the clinical diagnosis of anaphylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22500606\">",
"    <span class=\"h1\">",
"     CASE REPORT",
"    </span>",
"    &nbsp;&mdash;&nbsp;An 11 month old, 10 kg breastfed boy with eczema and a history of intermittent cough and wheeze suddenly developed a raised, red rash on his face, trunk, and extremities while being fed a snack consisting of a pudding made with egg, milk, and rice. His lips and cheeks became swollen and his eyes swelled shut. He vomited twice. Initially, he was irritable. Later, he became sleepy.",
"   </p>",
"   <p>",
"    He was taken immediately to the nearest emergency department. On arrival, he was noted to have generalized hives, periorbital swelling, tachypnea, and wheezing. His oxygen saturation was 92 percent in room air. He was treated with supplemental oxygen by facemask, and intramuscular injection of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    0.1 mg of a 1",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    (1:1,000) solution. The epinephrine injection was repeated 15 minutes later. He was then transferred to a children's hospital. On arrival there, three hours after his symptoms began, he was lethargic and had a fading, raised red rash superimposed on scaly red areas on his face, trunk, and extremities.",
"   </p>",
"   <p>",
"    The clinical diagnoses were (1) anaphylaxis and (2)",
"    <span class=\"nowrap\">",
"     eczema/atopic",
"    </span>",
"    dermatitis.",
"   </p>",
"   <p>",
"    Serum IgE levels were highly positive (10",
"    <span class=\"nowrap\">",
"     kUA/L)",
"    </span>",
"    to egg white and moderately positive (2",
"    <span class=\"nowrap\">",
"     kUA/L)",
"    </span>",
"    to egg yolk, but absent or undetectable to cow's milk and rice. Six weeks later, skin prick tests were positive to egg white and egg yolk, but negative to cow's milk and rice. No other food allergens were tested.",
"   </p>",
"   <p>",
"    Long-term risk reduction measures were implemented. His parents were given verbal and written instructions about how to avoid feeding him egg in any form. These instructions included a list of foods that commonly contain egg (eg, ice cream, pudding), and how to check the ingredient labels on processed foods and packaged foods for words that might indicate egg (eg, albumin, ovalbumin, lecithin) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33625/abstract/15\">",
"     15",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_table graphicRef53488 \" href=\"mobipreview.htm?7/56/8076\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A personalized written anaphylaxis emergency action plan was developed for him [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33625/abstract/16\">",
"     16",
"    </a>",
"    ]. An autoinjector containing 0.15 mg",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    was prescribed, despite the awareness that this dose is not ideal for a 10 kg infant because it exceeds 0.01",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    the recommended pediatric epinephrine dose for intramuscular injection. His parents were instructed on when and how to use an epinephrine autoinjector and referred to the relevant website for a review of these instructions. A cloth Medic-Alert bracelet stating \"anaphylaxis to egg\" was recommended because he attended a childcare center three days a week. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/48/18185?source=see_link\">",
"     \"Management of food allergy: Avoidance\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/44/5833?source=see_link\">",
"     \"Long-term management of patients with anaphylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22500613\">",
"    <span class=\"h1\">",
"     TRIGGERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Food is the most common trigger of anaphylaxis in infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33625/abstract/4-6,15,17-21\">",
"     4-6,15,17-21",
"    </a>",
"    ]; however, most of the other triggers of anaphylaxis in older age groups (eg, medications, natural rubber latex, insect stings and bites) have also been reported to trigger anaphylaxis in infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33625/abstract/22-29\">",
"     22-29",
"    </a>",
"    ]. Vaccines to prevent infectious disease rarely trigger anaphylaxis in patients of any age, including infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33625/abstract/28\">",
"     28",
"    </a>",
"    ]. Infants with nonimmune triggers such as cold air or cold water exposure, those with multiple anaphylaxis triggers from different classes of agents (eg, food, medication), and those without an identifiable anaphylaxis trigger (idiopathic anaphylaxis) should have a careful skin examination for urticaria",
"    <span class=\"nowrap\">",
"     pigmentosa/cutaneous",
"    </span>",
"    mastocytosis lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33625/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/0/38920?source=see_link\">",
"     \"Food-induced anaphylaxis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/17/34071?source=see_link\">",
"     \"Idiopathic anaphylaxis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/1/6170?source=see_link\">",
"     \"Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/13/18650?source=see_link\">",
"     \"Evaluation and diagnosis of mastocytosis (cutaneous and systemic)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/28/20937?source=see_link\">",
"     \"Mast cell activation disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22500620\">",
"    <span class=\"h2\">",
"     Foods",
"    </span>",
"    &nbsp;&mdash;&nbsp;Egg and cow's milk are common anaphylaxis triggers in infants, although any food can be implicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33625/abstract/4,6,15,17-21\">",
"     4,6,15,17-21",
"    </a>",
"    ]. This includes foods often presumed to be harmless (eg, goat&rsquo;s milk, sheep&rsquo;s milk, hypoallergenic formula cross-contaminated with cow&rsquo;s milk, and probiotics contaminated with cow&rsquo;s milk), foods infrequently given to infants (eg, sesame), and foods eaten by indigenous peoples (eg, seal meat and whale meat eaten by indigenous people in circumpolar regions).",
"   </p>",
"   <p>",
"    Infants can be sensitized to foods",
"    <em>",
"     in utero",
"    </em>",
"    , through breast milk, through direct ingestion of the food, or through accidental exposure (eg, food encountered and put in the mouth by crawling infant, or food given to the infant by an older sibling or caregiver) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33625/abstract/4-6,15,17-21\">",
"     4-6,15,17-21",
"    </a>",
"    ]. Skin contact with food, including skin care products containing foods, or inhalation of aerosolized food particles can potentially sensitize an infant (ie, lead to production of food-specific IgE), but rarely triggers anaphylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33625/abstract/11,15\">",
"     11,15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/42/43689?source=see_link\">",
"     \"Pathogenesis of food allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Caregivers may be unaware of the initial exposure to the food. Therefore, anaphylaxis after food ingestion is possible even when a caregiver reports that the infant had never been previously fed the culprit food.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22500627\">",
"    <span class=\"h2\">",
"     Other triggers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Less common triggers include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Medications (typically antibiotics, especially beta-lactam antibiotics, and NSAIDs such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      ; however, any medication, excipient, or contaminant may be implicated) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/53/33625/abstract/22-24\">",
"       22-24",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Natural rubber latex (eg, bottle nipples, pacifiers, toys) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/53/33625/abstract/25\">",
"       25",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Insect stings or bites [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/53/33625/abstract/26,27\">",
"       26,27",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Vaccines to protect against infectious diseases (rare trigger; approximate rate of occurrence: less than one per million injections) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/53/33625/abstract/28\">",
"       28",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Airborne environmental allergens (rare triggers; eg, cat, horse, and hamster or other rodent dander [epithelium])",
"     </li>",
"     <li>",
"      Nonimmune triggers (eg, cold water or cold air exposure)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22500634\">",
"    <span class=\"h1\">",
"     AT-RISK INFANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical risk factors and comorbid diseases that increase the risk of severe anaphylaxis have not yet been clearly defined in infants (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/13/1241?source=see_link\">",
"     \"Fatal anaphylaxis\"",
"    </a>",
"    ). The following are likely to be important:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Asthma and possibly other respiratory diseases (eg, bronchiolitis, croup)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Eczema/atopic",
"      </span>",
"      dermatitis",
"     </li>",
"     <li>",
"      Urticaria pigmentosa (especially if widely disseminated or bullous); mastocytosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/53/33625/abstract/29\">",
"       29",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Comorbidities in caregivers (eg, depression, cognitive dysfunction, or use of sedatives, ethanol, or recreational drugs) may play a role in failure to recognize symptoms and signs of anaphylaxis in infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33625/abstract/13,16\">",
"     13,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22500641\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In infancy, anaphylaxis is characterized by the sudden onset of symptoms and signs that typically involve two or more body organ systems (",
"    <a class=\"graphic graphic_table graphicRef72225 \" href=\"mobipreview.htm?22/43/23228\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33625/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/34/31272?source=see_link\">",
"     \"Apparent life-threatening event in infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22500648\">",
"    <span class=\"h2\">",
"     Other causes of acute skin symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute urticaria in infancy is commonly caused by an acute viral infection, or by a food, medication, or other allergen trigger. It is rare for hereditary angioedema to present in infancy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/1/6170?source=see_link\">",
"     \"Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/24/21898?source=see_link\">",
"     \"New onset urticaria\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/31/38391?source=see_link\">",
"     \"An overview of angioedema: Pathogenesis and causes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22500655\">",
"    <span class=\"h2\">",
"     Other causes of acute respiratory distress",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sudden onset of respiratory distress in infants may be caused by the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33625/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Congenital upper or lower respiratory tract obstruction (eg, laryngeal web, tracheal or laryngeal malacia, vascular ring). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/27/29114?source=see_link\">",
"       \"Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Acquired upper or lower respiratory tract obstruction (eg, foreign body aspiration, croup, asthma, bronchiolitis).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The various causes of acute respiratory distress in infants and children are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/61/7130?source=see_link\">",
"     \"Emergent evaluation of acute respiratory compromise in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/61/10201?source=see_link\">",
"     \"Emergent evaluation of acute upper airway obstruction in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/61/21464?source=see_link\">",
"     \"Assessment of stridor in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22500662\">",
"    <span class=\"h2\">",
"     Other causes of acute gastrointestinal symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sudden onset of gastrointestinal symptoms and signs in infants may be caused by the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33625/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Congenital gastrointestinal tract obstruction (eg, pyloric stenosis, malrotation)",
"     </li>",
"     <li>",
"      Acquired gastrointestinal tract obstruction (eg, intussusception)",
"     </li>",
"     <li>",
"      Gastroenteritis (viral or bacterial)",
"     </li>",
"     <li>",
"      Food protein-induced enterocolitis syndrome (FPIES), also termed dietary enterocolitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These causes are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/12/2250?source=see_link\">",
"     \"Food protein-induced enterocolitis syndrome (FPIES)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/60/24521?source=see_link\">",
"     \"Approach to the infant or child with nausea and vomiting\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/56/14216?source=see_link\">",
"     \"Epidemiology, pathogenesis, clinical presentation and diagnosis of viral gastroenteritis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/13/13529?source=see_link\">",
"     \"Evaluation of diarrhea in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22500669\">",
"    <span class=\"h2\">",
"     Other causes of acute central nervous system (CNS) symptoms and signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sudden onset of CNS symptoms may be caused by the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33625/abstract/11\">",
"     11",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/30/28136?source=see_link\">",
"     \"Evaluation of stupor and coma in children\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Seizure (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/25/21912?source=see_link\">",
"       \"Overview of the classification, etiology, and clinical features of pediatric seizures and epilepsy\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Head trauma (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/19/40249?source=see_link\">",
"       \"Child abuse: Evaluation and diagnosis of abusive head trauma in infants and children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Infections such as meningitis (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/8/28810?source=see_link\">",
"       \"Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Stroke (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/61/23513?source=see_link\">",
"       \"Ischemic stroke in children and young adults: Etiology and clinical features\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22500676\">",
"    <span class=\"h2\">",
"     Other causes of syncope",
"    </span>",
"    &nbsp;&mdash;&nbsp;These include life-threatening conditions such as arrhythmias and structural heart disease, and more benign conditions such as breath-holding spells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33625/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/10/36007?source=see_link\">",
"     \"Causes of syncope in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/51/24376?source=see_link\">",
"     \"Nonepileptic paroxysmal disorders in infancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22500683\">",
"    <span class=\"h2\">",
"     Other causes of shock",
"    </span>",
"    &nbsp;&mdash;&nbsp;These include hypovolemic shock, cardiogenic shock, other forms of distributive shock (eg, neurogenic shock), and septic shock (the latter involves hypovolemic, cardiogenic, and other elements) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33625/abstract/11\">",
"     11",
"    </a>",
"    ]. Feeding of the causal food in food protein-induced enterocolitis syndrome (FPIES) may lead to the development of shock associated with profuse vomiting and diarrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33625/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/49/14104?source=see_link\">",
"     \"Initial evaluation of shock in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/12/2250?source=see_link\">",
"     \"Food protein-induced enterocolitis syndrome (FPIES)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22500690\">",
"    <span class=\"h2\">",
"     Other entities",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other conditions, some of which are age-unique, may be difficult to differentiate from anaphylaxis in infants. These include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33625/abstract/11,30\">",
"     11,30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Congenital or metabolic disorders (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/58/24489?source=see_link\">",
"       \"Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Drug overdose, or poisoning from a chemical, toxic plant, or food",
"     </li>",
"     <li>",
"      Munchausen syndrome by proxy (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/16/36104?source=see_link\">",
"       \"Munchausen syndrome by proxy (medical child abuse)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Apparent life-threatening",
"      <span class=\"nowrap\">",
"       event/sudden",
"      </span>",
"      infant death syndrome (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/20/37194?source=see_link\">",
"       \"Sudden infant death syndrome: Risk factors and risk reduction strategies\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Hypotonic/hyporesponsive",
"      </span>",
"      episode",
"     </li>",
"     <li>",
"      Apnea and unresponsiveness in an former premature infant (born at or before 32 weeks gestation)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22500697\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF ACUTE ANAPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial management begins with rapid assessment (airway, breathing, circulation, responsiveness, skin, and body mass [weight]) and prompt injection of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine (adrenaline)",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33625/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link&amp;anchor=H18#H18\">",
"     \"Anaphylaxis: Rapid recognition and treatment\", section on 'Immediate management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     Epinephrine",
"    </a>",
"    should be given by intramuscular injection in the mid-anterolateral aspect of the thigh in a dose of 0.01",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    drawn up from a 1",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    (1:1000) solution. The time of the injection should be recorded. The dose can be repeated in 5 to 15 minutes if needed; most infants respond to one or two doses. Failure to inject epinephrine promptly in anaphylaxis may lead to",
"    <span class=\"nowrap\">",
"     hypoxic/ischemic",
"    </span>",
"    encephalopathy or to fatality. Intramuscular epinephrine injection may be associated with mild transient pharmacologic effects such as pallor, tremor, or tachycardia.",
"   </p>",
"   <p>",
"    Serious adverse effects such as ventricular arrhythmias and pulmonary edema can occur after",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    overdose, particularly if this occurs through the intravenous route. Examples include administration of an intravenous bolus dose or an overly rapid intravenous infusion, or a dosing error due to an intravenous infusion of the 1",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    (1:1000) solution that is appropriate for intramuscular solution instead of the dilute solutions that are appropriate for intravenous administration (0.1",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    [1:10,000] or 0.01",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    [1:100,000]).",
"   </p>",
"   <p>",
"    An",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    overdose can be difficult to recognize in infants. As an example, cough and respiratory distress commonly occur after a large epinephrine overdose that causes pulmonary edema, yet these symptoms are also common symptoms of anaphylaxis itself [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33625/abstract/11,31\">",
"     11,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For these reasons, we recommend that intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    should be administered to infants with anaphylaxis only by clinicians who are trained and experienced in titrating doses of epinephrine against blood pressure and cardiac rate and function as assessed by continuous noninvasive monitoring of heart rate, blood pressure, respiratory rate, and oxygenation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link&amp;anchor=H24#H24\">",
"     \"Anaphylaxis: Rapid recognition and treatment\", section on 'Epinephrine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infants with anaphylaxis should be treated with supplemental oxygen and intravenous fluids as needed. Adjunctive pharmacologic treatments include H1-antihistamines, beta-2 adrenergic agonists, and glucocorticoids, in addition to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    . These are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link&amp;anchor=H30#H30\">",
"     \"Anaphylaxis: Rapid recognition and treatment\", section on 'Adjunctive agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal observation period following successful treatment of an anaphylaxis episode in an infant is unknown; however, a minimum observation period of two hours, and preferably a period of eight hours is suggested. Biphasic anaphylaxis, defined as symptoms occurring without any further exposure to the trigger, from 1 to 72 hours after resolution of initial anaphylaxis symptoms, is less common in infants and children than in older patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33625/abstract/5,33\">",
"     5,33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link&amp;anchor=H38#H38\">",
"     \"Anaphylaxis: Rapid recognition and treatment\", section on 'Observation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22500704\">",
"    <span class=\"h1\">",
"     LONG-TERM MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The care upon resolution of an anaphylaxis episode is covered in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link&amp;anchor=H37#H37\">",
"     \"Anaphylaxis: Rapid recognition and treatment\", section on 'Care upon resolution'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/44/5833?source=see_link\">",
"     \"Long-term management of patients with anaphylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Trigger identification and avoidance in order to prevent recurrence of anaphylaxis are important aspects of long-term risk reduction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22500711\">",
"    <span class=\"h2\">",
"     Trigger identification and avoidance",
"    </span>",
"    &nbsp;&mdash;&nbsp;In infants, anaphylaxis is usually IgE-mediated and is usually triggered by food. Accordingly, food allergy will be used as the principal example in this section. Allergen sensitization can be determined by skin prick testing or by measurement of allergen-specific IgE in serum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33625/abstract/13\">",
"     13",
"    </a>",
"    ]. An individualized approach to testing is recommended, focusing upon the substances to which the infant was exposed in the minutes to hours immediately preceding the anaphylactic episode. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/12/5321?source=see_link\">",
"     \"Diagnostic evaluation of food allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2882440\">",
"    <span class=\"h2\">",
"     Foods",
"    </span>",
"    &nbsp;&mdash;&nbsp;Positive skin prick tests to food or elevated specific IgE levels to food indicate sensitization, but are not diagnostic of anaphylaxis or any other allergic disease. Sensitization is common in healthy infants in the general population; therefore, foods that the infant eats and tolerates without developing symptoms do not need to be tested. Panels of skin tests to foods and measurement of specific IgE levels to panels of foods are unnecessary and potentially misleading. Intradermal tests to foods are contraindicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33625/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/22/44391?source=see_link\">",
"     \"Overview of in vitro allergy tests\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/55/32633?source=see_link\">",
"     \"Overview of skin testing for allergic disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/12/5321?source=see_link&amp;anchor=H7#H7\">",
"     \"Diagnostic evaluation of food allergy\", section on 'Accuracy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Positive skin test results typically appear smaller in infants than in older children and adults. The food allergen-specific serum IgE levels that have a 95 percent predictive value for a positive failed food challenge are lower in infants than in older children and adults; however, infant norms are only available for a few foods such as egg and cow's milk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33625/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/12/5321?source=see_link\">",
"     \"Diagnostic evaluation of food allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In carefully selected infants, a medically-supervised, graded food challenge test conducted in an appropriately equipped healthcare setting staffed by trained and experienced healthcare professionals is sometimes needed to determine the risk of anaphylaxis recurrence. A challenge may be helpful if the clinical diagnosis of anaphylaxis is questionable or if there is little or no evidence of sensitization to the food implicated in triggering the episode.",
"    <strong>",
"     A challenge can trigger anaphylaxis and is therefore strictly contraindicated in an infant who has a convincing clinical history of anaphylaxis and is sensitized to the suspect food as evidenced by a positive skin prick test or an elevated specific IgE level",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33625/abstract/13,15\">",
"     13,15",
"    </a>",
"    ]",
"    <strong>",
"     .",
"    </strong>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/59/20409?source=see_link\">",
"     \"Oral food challenges for diagnosis and management of food allergies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prevention of future episodes of anaphylaxis requires vigilant allergen avoidance. This can be stressful for caregivers, especially if the implicated allergen is a food such as egg, cow&rsquo;s milk, or peanut that is ubiquitous in the diet and is commonly found in prepackaged or processed foods. Caregivers should be given written information about how to avoid exposing the infant to his or her confirmed food trigger of anaphylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33625/abstract/15,16,34\">",
"     15,16,34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/48/18185?source=see_link\">",
"     \"Management of food allergy: Avoidance\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/35/35379?source=see_link\">",
"     \"Patient information: Food allergy treatment and avoidance (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Immunomodulatory strategies to prevent food-induced anaphylaxis, for example, oral food allergen immunotherapy, appear promising but at present they remain research procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33625/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44057?source=see_link&amp;anchor=H3#H3\">",
"     \"Future therapies for food allergy\", section on 'Oral immunotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22500718\">",
"    <span class=\"h3\">",
"     Insect stings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaphylactic reactions to insect stings or bites are rare in infancy. Strict avoidance of exposure to the stinging or biting insect is the key to prevention of recurrent episodes. However, if the anaphylactic reaction occurred to a Hymenoptera sting, and sensitization to stinging insect venom has been confirmed, allergen-specific subcutaneous immunotherapy is indicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33625/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/34/16936?source=see_link\">",
"     \"Hymenoptera venom immunotherapy: Efficacy, indications, and mechanism of action\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22500725\">",
"    <span class=\"h3\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common approach to management of infants who have medication-induced anaphylaxis is to avoid giving the implicated agent and substitute a non-cross-reacting medication, preferably from a different therapeutic class. Clinician-supervised desensitization to the medication that triggered the anaphylaxis is indicated if an effective and safe substitute pharmacologic agent is not available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33625/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22500732\">",
"    <span class=\"h3\">",
"     Vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaphylaxis to a vaccine for prevention of an infectious disease is rare. When it occurs, it is usually due to a vaccine constituent such as gelatin, egg, latex, or yeast, rather than to the microbial agent in the vaccine. Specific protocols for evaluation and management of patients with a history of anaphylaxis to a vaccine are available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33625/abstract/28,31\">",
"     28,31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/5/43097?source=see_link\">",
"     \"Allergic reactions to vaccines\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22500739\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;For infants with anaphylaxis to natural rubber latex, airborne environmental allergens, or non-immune triggers, caregivers should be given written instructions about how to avoid exposing the infant to the trigger [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33625/abstract/25,31\">",
"     25,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22500746\">",
"    <span class=\"h2\">",
"     Preparedness to treat a recurrence of anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Caregivers should be instructed in how to treat anaphylaxis in the event of recurrence after unintentional exposure to the triggering allergen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33625/abstract/16,31,35\">",
"     16,31,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22500753\">",
"    <span class=\"h2\">",
"     Epinephrine for first-aid treatment of anaphylaxis in the community",
"    </span>",
"    &nbsp;&mdash;&nbsp;Caregivers of infants who are at risk for anaphylaxis should be equipped with an",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    autoinjector [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33625/abstract/16,31,32,35\">",
"     16,31,32,35",
"    </a>",
"    ]. A personalized written anaphylaxis emergency action plan for the infant should be developed with the caregiver's input [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33625/abstract/16,35\">",
"     16,35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link&amp;anchor=H40#H40\">",
"     \"Anaphylaxis: Rapid recognition and treatment\", section on 'Anaphylaxis emergency action plan'",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/30/28134?source=see_link\">",
"     \"Patient information: Use of an epinephrine autoinjector (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The lowest dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    available in an autoinjector is 0.15 mg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33625/abstract/11,36\">",
"     11,36",
"    </a>",
"    ]. Most infants weigh less than 15 kg. This presents a dilemma for clinicians wishing to prescribe the recommended epinephrine dose of 0.01",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (see",
"    <a class=\"local\" href=\"#H22500606\">",
"     'Case report'",
"    </a>",
"    above). Caregivers need instruction and regular coaching in how to use an epinephrine autoinjector correctly and safely in an infant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33625/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Autoinjector needle length might also be a concern in some infants. The optimal needle length for intramuscular injection in the thigh in infants and toddlers is 2.2 to 2.5 cm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33625/abstract/38\">",
"     38",
"    </a>",
"    ]. However, most",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    autoinjector needles are approximately 1.43 cm, and therefore might be too short to provide intramuscular injection for some infants and toddlers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33625/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infants with anaphylaxis occurring in community settings are less likely than patients in older age groups to receive an",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    injection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33625/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Caregivers without medical training find it difficult to draw up an infant dose from an ampule of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    rapidly and accurately; therefore, this alternative is not recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33625/abstract/41\">",
"     41",
"    </a>",
"    ]. Additionally, other alternatives such as an unsealed prefilled syringe are not recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33625/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/17/23832?source=see_link\">",
"     \"Prescribing epinephrine for anaphylaxis self-treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22500789\">",
"    <span class=\"h3\">",
"     H1-antihistamines",
"    </span>",
"    &nbsp;&mdash;&nbsp;H1-antihistamines relieve urticaria, but do not relieve upper or lower airway obstruction, hypotension, or shock. They are not life-saving and therefore should not be substituted for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33625/abstract/31,32,43\">",
"     31,32,43",
"    </a>",
"    ]. In addition, first (old)-generation H1-antihistamines often cause clinically relevant sedation and associated lack of responsiveness that can hamper the recognition of progression of an anaphylaxis episode [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33625/abstract/31,32,43-45\">",
"     31,32,43-45",
"    </a>",
"    ]. In overdose, they can also lead to respiratory arrest and death in infants. The use of H1-antihistamines as adjunctive treatment for anaphylaxis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link&amp;anchor=H31#H31\">",
"     \"Anaphylaxis: Rapid recognition and treatment\", section on 'H1 antihistamines'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2882902\">",
"    <span class=\"h3\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids are given to prevent biphasic or protracted reactions; however, these types of reactions are uncommon in anaphylaxis in infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33625/abstract/5\">",
"     5",
"    </a>",
"    ]. The use of glucocorticoids as adjunctive treatment for anaphylaxis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link&amp;anchor=H34#H34\">",
"     \"Anaphylaxis: Rapid recognition and treatment\", section on 'Glucocorticoids'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22500760\">",
"    <span class=\"h2\">",
"     Management of comorbidities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Comorbidities in the infant (eg, asthma, urticaria",
"    <span class=\"nowrap\">",
"     pigmentosa/mastocytosis)",
"    </span>",
"    or in the caregiver (eg, depression, substance abuse) should be managed appropriately [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33625/abstract/11,16\">",
"     11,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22500767\">",
"    <span class=\"h2\">",
"     Medical identification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants with a history of anaphylaxis who are in the care of someone other than their parents or other primary caregiver(s) should wear medical identification. In young infants, this may be in the form of a T-shirt or Velcro patch (for clothing) with a specific allergy alert message (eg, \"I am allergic to egg\"). Medical identification bracelets made of fabric are available for older infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33625/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/44/5833?source=see_link\">",
"     \"Long-term management of patients with anaphylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22500774\">",
"    <span class=\"h2\">",
"     Anaphylaxis education",
"    </span>",
"    &nbsp;&mdash;&nbsp;Being responsible for the recognition and management of an episode of anaphylaxis, particularly the possibility of having to inject",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    , provokes high anxiety levels in caregivers of infants with a history of anaphylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33625/abstract/11,16,34,46\">",
"     11,16,34,46",
"    </a>",
"    ]. Individualized",
"    <span class=\"nowrap\">",
"     teaching/coaching",
"    </span>",
"    sessions help to diminish this anxiety and should be repeated at regular intervals. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/44/5833?source=see_link\">",
"     \"Long-term management of patients with anaphylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22500781\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anaphylaxis is likely under-recognized in infancy because many episodes are \"first\" episodes, infants cannot describe their symptoms, and many of their signs are either nonspecific or are commonly seen for other reasons in healthy infants. Diagnosis therefore depends upon a high index of suspicion, and meticulous history of antecedent exposures and events, chronologic development of symptoms, and careful physical examination. (See",
"      <a class=\"local\" href=\"#H22500599\">",
"       'Clinical manifestations and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Food is the most common trigger of anaphylaxis in infants. (See",
"      <a class=\"local\" href=\"#H22500613\">",
"       'Triggers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of anaphylaxis in infants includes congenital and acquired causes of acute",
"      <span class=\"nowrap\">",
"       urticaria/angioedema,",
"      </span>",
"      acute respiratory distress, acute gastrointestinal symptoms, or shock. Some conditions in the differential diagnosis, such as food protein-induced enterocolitis, are age-unique. (See",
"      <a class=\"local\" href=\"#H22500641\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Medical management is extrapolated from the treatment of anaphylaxis in older children and adults. The initial medication of choice is",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      injected intramuscularly in the thigh. (See",
"      <a class=\"local\" href=\"#H22500697\">",
"       'Management of acute anaphylaxis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link\">",
"       \"Anaphylaxis: Rapid recognition and treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Long-term risk reduction measures include confirmation of anaphylaxis triggers suggested by the history, instruction of caregivers in how to identify triggers and avoid exposing the infant to them, and preparedness for treatment of future anaphylactic episodes. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/44/5833?source=see_link\">",
"       \"Long-term management of patients with anaphylaxis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/17/23832?source=see_link\">",
"       \"Prescribing epinephrine for anaphylaxis self-treatment\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33625/abstract/1\">",
"      Decker WW, Campbell RL, Manivannan V, et al. The etiology and incidence of anaphylaxis in Rochester, Minnesota: a report from the Rochester Epidemiology Project. J Allergy Clin Immunol 2008; 122:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33625/abstract/2\">",
"      Ross MP, Ferguson M, Street D, et al. Analysis of food-allergic and anaphylactic events in the National Electronic Injury Surveillance System. J Allergy Clin Immunol 2008; 121:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33625/abstract/3\">",
"      Lin RY, Anderson AS, Shah SN, Nurruzzaman F. Increasing anaphylaxis hospitalizations in the first 2 decades of life: New York State, 1990 -2006. Ann Allergy Asthma Immunol 2008; 101:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33625/abstract/4\">",
"      Mehl A, Wahn U, Niggemann B. Anaphylactic reactions in children--a questionnaire-based survey in Germany. Allergy 2005; 60:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33625/abstract/5\">",
"      Huang F, Chawla K, J&auml;rvinen KM, Nowak-W��grzyn A. Anaphylaxis in a New York City pediatric emergency department: triggers, treatments, and outcomes. J Allergy Clin Immunol 2012; 129:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33625/abstract/6\">",
"      de Silva IL, Mehr SS, Tey D, Tang ML. Paediatric anaphylaxis: a 5 year retrospective review. Allergy 2008; 63:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33625/abstract/7\">",
"      Pumphrey RS, Gowland MH. Further fatal allergic reactions to food in the United Kingdom, 1999-2006. J Allergy Clin Immunol 2007; 119:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33625/abstract/8\">",
"      Bock SA, Mu&ntilde;oz-Furlong A, Sampson HA. Fatalities due to anaphylactic reactions to foods. J Allergy Clin Immunol 2001; 107:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33625/abstract/9\">",
"      Sampson HA, Mendelson L, Rosen JP. Fatal and near-fatal anaphylactic reactions to food in children and adolescents. N Engl J Med 1992; 327:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33625/abstract/10\">",
"      Rudders SA, Banerji A, Clark S, Camargo CA Jr. Age-related differences in the clinical presentation of food-induced anaphylaxis. J Pediatr 2011; 158:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33625/abstract/11\">",
"      Simons FE. Anaphylaxis in infants: can recognition and management be improved? J Allergy Clin Immunol 2007; 120:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33625/abstract/12\">",
"      Sampson HA, Mu&ntilde;oz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006; 117:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33625/abstract/13\">",
"      Simons FE, Frew AJ, Ansotegui IJ, et al. Risk assessment in anaphylaxis: current and future approaches. J Allergy Clin Immunol 2007; 120:S2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33625/abstract/14\">",
"      Komarow HD, Hu Z, Brittain E, et al. Serum tryptase levels in atopic and nonatopic children. J Allergy Clin Immunol 2009; 124:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33625/abstract/15\">",
"      Boyce JA, Assa'ad A, Burks AW, et al. Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report. J Allergy Clin Immunol 2010; 126:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33625/abstract/16\">",
"      Simons FE. Anaphylaxis, killer allergy: long-term management in the community. J Allergy Clin Immunol 2006; 117:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33625/abstract/17\">",
"      Pessler F, Nejat M. Anaphylactic reaction to goat's milk in a cow's milk-allergic infant. Pediatr Allergy Immunol 2004; 15:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33625/abstract/18\">",
"      Levin ME, Motala C, Lopata AL. Anaphylaxis in a milk-allergic child after ingestion of soy formula cross-contaminated with cow's milk protein. Pediatrics 2005; 116:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33625/abstract/19\">",
"      Lee TT, Morisset M, Astier C, et al. Contamination of probiotic preparations with milk allergens can cause anaphylaxis in children with cow's milk allergy. J Allergy Clin Immunol 2007; 119:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33625/abstract/20\">",
"      Aaronov D, Tasher D, Levine A, et al. Natural history of food allergy in infants and children in Israel. Ann Allergy Asthma Immunol 2008; 101:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33625/abstract/21\">",
"      Moore LM, Rathkopf MM, Sanner CJ, et al. Seal and whale meat: two newly recognized food allergies. Ann Allergy Asthma Immunol 2007; 98:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33625/abstract/22\">",
"      Tayman C, Mete E, Bayrak O, et al. Unexpected cefazolin anaphylaxis in a 5-month-old girl. Pediatr Emerg Care 2008; 24:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33625/abstract/23\">",
"      Soyer OU, Ozen C, Tiras U, Dallar Y. Anaphylaxis in a neonate caused by ceftazidime. Allergy 2010; 65:1486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33625/abstract/24\">",
"      Blossom DB, Kallen AJ, Patel PR, et al. Outbreak of adverse reactions associated with contaminated heparin. N Engl J Med 2008; 359:2674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33625/abstract/25\">",
"      Kimata H. Latex allergy in infants younger than 1 year. Clin Exp Allergy 2004; 34:1910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33625/abstract/26\">",
"      More DR, Kohlmeier RE, Hoffman DR. Fatal anaphylaxis to indoor native fire ant stings in an infant. Am J Forensic Med Pathol 2008; 29:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33625/abstract/27\">",
"      Ramesh Bhat Y, Vinayaka G, Sushma S. Systemic allergic reaction to a caterpillar in a 3-month-old infant. Ann Trop Paediatr 2010; 30:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33625/abstract/28\">",
"      Bohlke K, Davis RL, Marcy SM, et al. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics 2003; 112:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33625/abstract/29\">",
"      Brockow K, Jofer C, Behrendt H, Ring J. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy 2008; 63:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33625/abstract/30\">",
"      Zanoni G, Gottin L, Boner A, et al. Case discussion of an immediate serious reaction to hexavalent vaccine mistaken for anaphylaxis. Br J Clin Pharmacol 2010; 70:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33625/abstract/31\">",
"      Simons FE, Ardusso LR, Bil&ograve; MB, et al. World Allergy Organization anaphylaxis guidelines: summary. J Allergy Clin Immunol 2011; 127:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33625/abstract/32\">",
"      Soar J, Pumphrey R, Cant A, et al. Emergency treatment of anaphylactic reactions--guidelines for healthcare providers. Resuscitation 2008; 77:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33625/abstract/33\">",
"      Mehr S, Liew WK, Tey D, Tang ML. Clinical predictors for biphasic reactions in children presenting with anaphylaxis. Clin Exp Allergy 2009; 39:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33625/abstract/34\">",
"      Oude Elberink JN. Significance and rationale of studies of health-related quality of life in anaphylactic disorders. Curr Opin Allergy Clin Immunol 2006; 6:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33625/abstract/35\">",
"      Simons FE. Anaphylaxis: evidence-based long-term risk reduction in the community. Immunol Allergy Clin North Am 2007; 27:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33625/abstract/36\">",
"      Simons FE. First-aid treatment of anaphylaxis to food: focus on epinephrine. J Allergy Clin Immunol 2004; 113:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33625/abstract/37\">",
"      Simons FE, Edwards ES, Read EJ Jr, et al. Voluntarily reported unintentional injections from epinephrine auto-injectors. J Allergy Clin Immunol 2010; 125:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33625/abstract/38\">",
"      Lippert WC, Wall EJ. Optimal intramuscular needle-penetration depth. Pediatrics 2008; 122:e556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33625/abstract/39\">",
"      Stecher D, Bulloch B, Sales J, et al. Epinephrine auto-injectors: is needle length adequate for delivery of epinephrine intramuscularly? Pediatrics 2009; 124:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33625/abstract/40\">",
"      Simons FE, Clark S, Camargo CA Jr. Anaphylaxis in the community: learning from the survivors. J Allergy Clin Immunol 2009; 124:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33625/abstract/41\">",
"      Simons FE, Chan ES, Gu X, Simons KJ. Epinephrine for the out-of-hospital (first-aid) treatment of anaphylaxis in infants: is the ampule/syringe/needle method practical? J Allergy Clin Immunol 2001; 108:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33625/abstract/42\">",
"      Rawas-Qalaji M, Simons FE, Collins D, Simons KJ. Long-term stability of epinephrine dispensed in unsealed syringes for the first-aid treatment of anaphylaxis. Ann Allergy Asthma Immunol 2009; 102:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33625/abstract/43\">",
"      Simons FE. Advances in H1-antihistamines. N Engl J Med 2004; 351:2203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33625/abstract/44\">",
"      Starke PR, Weaver J, Chowdhury BA. Boxed warning added to promethazine labeling for pediatric use. N Engl J Med 2005; 352:2653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33625/abstract/45\">",
"      Sheikh A, Ten Broek V, Brown SG, Simons FE. H1-antihistamines for the treatment of anaphylaxis: Cochrane systematic review. Allergy 2007; 62:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33625/abstract/46\">",
"      Bansal PJ, Marsh R, Patel B, Tobin MC. Recognition, evaluation, and treatment of anaphylaxis in the child care setting. Ann Allergy Asthma Immunol 2005; 94:55.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5750 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-6DAE62D42F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_53_33625=[""].join("\n");
var outline_f32_53_33625=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22500781\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22500592\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22500599\">",
"      CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22500606\">",
"      CASE REPORT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22500613\">",
"      TRIGGERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22500620\">",
"      Foods",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22500627\">",
"      Other triggers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22500634\">",
"      AT-RISK INFANTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22500641\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22500648\">",
"      Other causes of acute skin symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22500655\">",
"      Other causes of acute respiratory distress",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22500662\">",
"      Other causes of acute gastrointestinal symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22500669\">",
"      Other causes of acute central nervous system (CNS) symptoms and signs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22500676\">",
"      Other causes of syncope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22500683\">",
"      Other causes of shock",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22500690\">",
"      Other entities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22500697\">",
"      MANAGEMENT OF ACUTE ANAPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22500704\">",
"      LONG-TERM MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22500711\">",
"      Trigger identification and avoidance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2882440\">",
"      Foods",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22500718\">",
"      - Insect stings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22500725\">",
"      - Medications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22500732\">",
"      - Vaccines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22500739\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22500746\">",
"      Preparedness to treat a recurrence of anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22500753\">",
"      Epinephrine for first-aid treatment of anaphylaxis in the community",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22500789\">",
"      - H1-antihistamines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2882902\">",
"      - Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22500760\">",
"      Management of comorbidities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22500767\">",
"      Medical identification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22500774\">",
"      Anaphylaxis education",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22500781\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/5750\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5750|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/43/23228\" title=\"table 1\">",
"      Anaphylaxis diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/20/36172\" title=\"table 2\">",
"      Symptoms and signs of anaphylaxis in infants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/56/8076\" title=\"table 3\">",
"      Ingredient label terms for egg",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/5/43097?source=related_link\">",
"      Allergic reactions to vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/31/38391?source=related_link\">",
"      An overview of angioedema: Pathogenesis and causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/34/31272?source=related_link\">",
"      Apparent life-threatening event in infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/60/24521?source=related_link\">",
"      Approach to the infant or child with nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/61/21464?source=related_link\">",
"      Assessment of stridor in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/24/19847?source=related_link\">",
"      Biphasic and protracted anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/10/36007?source=related_link\">",
"      Causes of syncope in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/19/40249?source=related_link\">",
"      Child abuse: Evaluation and diagnosis of abusive head trauma in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/8/28810?source=related_link\">",
"      Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/1/6170?source=related_link\">",
"      Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/27/29114?source=related_link\">",
"      Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/12/5321?source=related_link\">",
"      Diagnostic evaluation of food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/61/7130?source=related_link\">",
"      Emergent evaluation of acute respiratory compromise in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/61/10201?source=related_link\">",
"      Emergent evaluation of acute upper airway obstruction in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/56/14216?source=related_link\">",
"      Epidemiology, pathogenesis, clinical presentation and diagnosis of viral gastroenteritis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/13/18650?source=related_link\">",
"      Evaluation and diagnosis of mastocytosis (cutaneous and systemic)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/13/13529?source=related_link\">",
"      Evaluation of diarrhea in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/30/28136?source=related_link\">",
"      Evaluation of stupor and coma in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/13/1241?source=related_link\">",
"      Fatal anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/12/2250?source=related_link\">",
"      Food protein-induced enterocolitis syndrome (FPIES)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/0/38920?source=related_link\">",
"      Food-induced anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44057?source=related_link\">",
"      Future therapies for food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/34/16936?source=related_link\">",
"      Hymenoptera venom immunotherapy: Efficacy, indications, and mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/17/34071?source=related_link\">",
"      Idiopathic anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/58/24489?source=related_link\">",
"      Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/49/14104?source=related_link\">",
"      Initial evaluation of shock in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/61/23513?source=related_link\">",
"      Ischemic stroke in children and young adults: Etiology and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/54/40809?source=related_link\">",
"      Laboratory tests to support the clinical diagnosis of anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/44/5833?source=related_link\">",
"      Long-term management of patients with anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/48/18185?source=related_link\">",
"      Management of food allergy: Avoidance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/28/20937?source=related_link\">",
"      Mast cell activation disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/16/36104?source=related_link\">",
"      Munchausen syndrome by proxy (medical child abuse)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/24/21898?source=related_link\">",
"      New onset urticaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/51/24376?source=related_link\">",
"      Nonepileptic paroxysmal disorders in infancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/59/20409?source=related_link\">",
"      Oral food challenges for diagnosis and management of food allergies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/22/44391?source=related_link\">",
"      Overview of in vitro allergy tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/55/32633?source=related_link\">",
"      Overview of skin testing for allergic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/25/21912?source=related_link\">",
"      Overview of the classification, etiology, and clinical features of pediatric seizures and epilepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/42/43689?source=related_link\">",
"      Pathogenesis of food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/35/35379?source=related_link\">",
"      Patient information: Food allergy treatment and avoidance (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/30/28134?source=related_link\">",
"      Patient information: Use of an epinephrine autoinjector (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/17/23832?source=related_link\">",
"      Prescribing epinephrine for anaphylaxis self-treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/20/37194?source=related_link\">",
"      Sudden infant death syndrome: Risk factors and risk reduction strategies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_53_33626="Risk factors for calcium stones in adults";
var content_f32_53_33626=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Risk factors for calcium stones in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/53/33626/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/53/33626/contributors\">",
"     Gary C Curhan, MD, ScD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/53/33626/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/53/33626/contributors\">",
"     Stanley Goldfarb, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/53/33626/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/53/33626/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/53/33626/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal stone disease (nephrolithiasis) is a relatively common problem [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Older studies estimated that 12 percent of men and 5 percent of women will have at least one symptomatic stone by the age of 70 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a report from the third National Health and Nutrition Examination Survey, the population prevalence increased from 3.8 percent in the period 1976 to 1980 to 5.2 percent in the years 1988 to 1994 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/2\">",
"     2",
"    </a>",
"    ]. The prevalence increased in men and women, and whites and blacks. However, the incidence rates since then may have leveled off [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 75 percent of patients with nephrolithiasis form calcium stones, most of which are composed primarily of calcium oxalate or, less often, calcium phosphate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. Pure uric acid stones make up less than 10 percent of all stones.",
"   </p>",
"   <p>",
"    This topic provides an overview of the pathogenesis and risk factors for calcium nephrolithiasis. The evaluation and management of the patient with kidney stones, prevention of recurrent calcium stones, and related topics are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/50/20266?source=see_link\">",
"     \"Diagnosis and acute management of suspected nephrolithiasis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/22/29033?source=see_link\">",
"     \"Evaluation of the adult patient with established nephrolithiasis and treatment if stone composition is unknown\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/2/38953?source=see_link\">",
"     \"Prevention of recurrent calcium stones in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stones are more likely to occur when one or more factors are present that lead sequentially to supersaturation of the urine, the formation of crystals, and their subsequent aggregation into a clinically detectable stone. Even individuals without nephrolithiasis can excrete crystals; however, calcium oxalate stone formers are more likely to have crystalluria than controls, and the presence of crystalluria substantially increases the likelihood of stone formation (",
"    <a class=\"graphic graphic_picture graphicRef65169 graphicRef67694 \" href=\"mobipreview.htm?14/28/14788\">",
"     picture 1A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is substantial debate about where the initiating event for stone formation occurs. In particular, it is unclear how crystals formed in the tubules become a stone in some patients, rather than being washed away by the high rate of urine flow. Some have proposed that crystal aggregates can become large enough to become anchored in the renal tubules (usually at the collecting duct) or to bind to the tubular epithelium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/6,7\">",
"     6,7",
"    </a>",
"    ], and slowly increase in size over time to form stones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, this paradigm is changing because emerging data suggest that the initial site of stone formation is the renal medullary interstitium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Calcium phosphate crystals may form in the interstitium, and they eventually get extruded and adhere at the renal papilla, forming the classic Randall's plaque [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Calcium oxalate or calcium phosphate crystals may then deposit on top of this calcium phosphate nidus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/13\">",
"     13",
"    </a>",
"    ]. In some situations, crystals may aggregate in dilated ducts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/14\">",
"     14",
"    </a>",
"    ]. These observations are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/43/17081?source=see_link&amp;anchor=H3#H3\">",
"     \"Nephrocalcinosis\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of metabolic, anatomic, urinary and dietary factors that predispose to the development of calcium stones (",
"    <a class=\"graphic graphic_table graphicRef78303 \" href=\"mobipreview.htm?1/35/1596\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/4,15-20\">",
"     4,15-20",
"    </a>",
"    ]. The frequency with which these different risk factors occur in patients with recurrent stone disease and the role of genetic susceptibility are reviewed at the end of this topic. The importance of individual risk factors varies by age and sex. A discussion of treatment options can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/2/38953?source=see_link\">",
"     \"Prevention of recurrent calcium stones in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The urine pH contributes to the likelihood of formation of certain stones. An acid urine (typical for most individuals) favors uric acid precipitation; although previously believed to be a nidus for calcium oxalate stones, this has not been supported by multiple studies. An alkaline urine (as may be seen with urinary tract infections and renal tubular acidosis but also in individuals with higher dietary alkali intake) promotes calcium phosphate stone formation. Calcium oxalate stones are not pH-dependent in the physiologic range. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Hypocitraturia'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Calcium phosphate and calcium oxalate stones share some risk factors such as low urine volume, high urine calcium, and low urine citrate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/21\">",
"     21",
"    </a>",
"    ]. However, there are also distinct risk factors for each type of stone. As an example, hyperoxaluria is a risk factor for calcium oxalate stones, while higher urine pH is a risk factor for calcium phosphate stones. Because the approach to stone prevention depends upon the composition of the stone, it is essential that every attempt is made to retrieve a passed or removed stone and to send it for analysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Hypercalciuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;An elevated urinary calcium excretion, with or without other risk factors, is observed in up to one-half of idiopathic calcium stone formers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/22\">",
"     22",
"    </a>",
"    ]. In addition to predisposing to stone disease, hypercalciuria may also cause hematuria in the absence of overt stone formation. It is presumed that the hematuria in this setting results from local tissue damage induced by small crystal aggregates. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/59/34746?source=see_link\">",
"     \"Etiology and evaluation of hematuria in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Definition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypercalciuria has been variably defined and each definition has limitations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urinary calcium excretion greater than 250",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (6.24",
"      <span class=\"nowrap\">",
"       mmol/day)",
"      </span>",
"      in women and greater than 300",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (7.49",
"      <span class=\"nowrap\">",
"       mmol/day)",
"      </span>",
"      in men were the traditional definitions. However, there is no clear justification from the perspective of stone formation why a man is allowed to have more calcium in his urine than a woman. The cutpoints used in published research studies and clinical laboratories vary substantially, with some using the same value for both genders, such as greater than 200",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (4.99",
"      <span class=\"nowrap\">",
"       mmol/day).",
"      </span>",
"     </li>",
"     <li>",
"      Urinary calcium excretion greater than 4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (0.1",
"      <span class=\"nowrap\">",
"       mmol/kg)",
"      </span>",
"      per day. The problem with this definition is that it allows heavier individuals to have more calcium in their urine than lighter individuals. While this may be appropriate from a calcium balance standpoint, it does not make sense for stone formation. Since urine volume does not increase with weight gain, a 'normal' urinary calcium excretion in a heavier person would result in a higher concentration of calcium in the urine (and a higher risk).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An additional problem with both definitions is that the risk of stone formation rises with increasing urinary calcium excretion above 100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (2.5",
"    <span class=\"nowrap\">",
"     mmol/day),",
"    </span>",
"    not at some arbitrary threshold value. This was illustrated in a cross-sectional study of 3350 men and women, of whom 2237 had a history of nephrolithiasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/22\">",
"     22",
"    </a>",
"    ]. Stone disease was determined from biennial questionnaires; medical record review in the later part of the study confirmed the diagnosis in over 90 percent. Although stone composition was unknown in many cases, the demographics of the participants suggested that approximately 80 percent were likely to have had calcium oxalate stones.",
"   </p>",
"   <p>",
"    Compared to a 24-hour urinary calcium excretion below 100 mg, the relative risk of being a stone former in older women was 1.52 for a urinary calcium of 150 to 199",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    1.84 for a urinary calcium of 200 to 249",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (4.99 to 6.23",
"    <span class=\"nowrap\">",
"     mmol/day),",
"    </span>",
"    and 1.93 for a urinary calcium of 250 to 299",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (6.24 to 7.48",
"    <span class=\"nowrap\">",
"     mmol/day).",
"    </span>",
"    The relative risk increased further at clearly hypercalciuric levels: 2.68 and 4.94 at urinary calcium of 300 to 349",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (7.49 to 8.72",
"    <span class=\"nowrap\">",
"     mmol/day)",
"    </span>",
"    and greater than 350",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (8.73",
"    <span class=\"nowrap\">",
"     mmol/day),",
"    </span>",
"    respectively. Similar results were found in men and younger women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Possible reasons for hypercalciuria in calcium-stone formers include primary hyperparathyroidism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/23,24\">",
"     23,24",
"    </a>",
"    ], and chronic acidemia. However, most calcium-stone formers with hypercalciuria do not have either of these disorders. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/26/23973?source=see_link\">",
"     \"Nephrolithiasis in renal tubular acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    High urine calcium excretion without an identifiable cause is often referred to as idiopathic hypercalciuria. Conceptually, it is useful to consider three contributions to higher urinary calcium excretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased intestinal absorption (\"absorptive hypercalciuria\") in which there is an increase in intestinal calcium absorption [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/27\">",
"       27",
"      </a>",
"      ]. However, dietary calcium intake should not be restricted unless it is excessive (&gt; 2000",
"      <span class=\"nowrap\">",
"       mg/d).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Calcium'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Increased bone resorption (\"resorptive hypercalciuria\") in which the source of the excess calcium may be bone.",
"     </li>",
"     <li>",
"      Increased renal losses (\"renal hypercalciuria\") in which there is a defect in renal tubular calcium reabsorption.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical significance of this classification is uncertain. Most individuals with hypercalciuria exhibit more than one abnormality. Thus, it is not necessary for clinical purposes to perform calcium loading or calcium restriction tests.",
"   </p>",
"   <p>",
"    Although the genetic causes of the common types of stone disease are unknown, it has been suggested that idiopathic hypercalciuria is transmitted as an autosomal dominant trait. Reports have suggested gene defects localized to chromosomal areas 9q33.2-q34.2 and 1q23-q24 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/28,29\">",
"     28,29",
"    </a>",
"    ], but others have been unsuccessful in identifying a locus. This may be due to the likely substantial heterogeneity of this disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. It is likely that the common form of nephrolithiasis is a complex genetic disorder that is influenced by environmental factors such as dietary intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Idiopathic hypercalciuria may be associated with a slightly higher plasma concentration of calcitriol (1,25-dihydroxyvitamin D3) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/4,34,35\">",
"     4,34,35",
"    </a>",
"    ], although the values are rarely above the normal range. A high animal protein intake may contribute to both the high calcitriol levels and the tendency to kidney stone formation in this setting. The influence of plasma 25-hydroxyvitamin D is uncertain. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Dietary risk factors'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Elevated calcitriol levels can enhance calcium excretion both by increasing intestinal calcium absorption (absorptive hypercalciuria) and by promoting bone resorption (resorptive hypercalciuria) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/36\">",
"     36",
"    </a>",
"    ]. The latter effect has important clinical implications, since lowering calcium intake may not dramatically reduce urine calcium excretion and may result in negative calcium balance, with the lost calcium coming from bone. If prolonged, the negative calcium balance can lead to osteopenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/34,37-40\">",
"     34,37-40",
"    </a>",
"    ]. This may be particularly important since some untreated patients with hypercalciuria already have diminished bone density, due possibly to increased bone resorption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The factors responsible for the higher calcitriol levels in some patients with idiopathic hypercalciuria are not well understood. It has been proposed that a urinary phosphate leak might be the primary defect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/41\">",
"     41",
"    </a>",
"    ], leading to a mild reduction in the plasma phosphate concentration that would then stimulate the synthesis of calcitriol.",
"   </p>",
"   <p>",
"    In some patients, the mechanism for the urinary phosphate leak may be mutations in the sodium-hydrogen exchanger regulator factor 1 (NHERF1), which interacts with both renal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/22/5480?source=see_link\">",
"     sodium phosphate",
"    </a>",
"    transporters to facilitate normal phosphate regulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/42\">",
"     42",
"    </a>",
"    ]. Some evidence for this hypothesis was noted in a study of 94 patients with renal calcium lithiasis or bone demineralization, of whom seven had mutations in NHERF1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/43\">",
"     43",
"    </a>",
"    ]. All seven had low maximal reabsorption of phosphate, hypophosphatemia, and increased calcitriol levels. Expression of mutant NHERF1 proteins in kidney cells did not alter basal phosphate uptake; rather, they caused increased cyclic AMP generation by parathyroid hormone, resulting in the inhibition of phosphate transport. Further study is required to better clarify the increased risk of renal stone formation with abnormalities in NHERF1. A role for fibroblast growth factor-23 has also been suggested [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/44,45\">",
"     44,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypophosphatemia also has other effects that can promote stone formation, including increased bone resorption and reduced tubular calcium reabsorption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. This explanatory mechanism for high calcitriol levels probably applies to only a small number of patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/15/9462?source=see_link\">",
"     \"Metabolism of vitamin D\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Experimental results in an animal model suggest that hyperresponsiveness of the gene for the vitamin D receptor to low concentrations of 1,25-dihydroxyvitamin D3 is one way to induce hypercalciuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/26\">",
"     26",
"    </a>",
"    ]. In hypercalciuric stone-forming rats, stabilization of vitamin D receptor mRNA resulted in markedly increased levels of both the receptor and receptor-related events in response to minimal concentrations of 1,25-dihydroxyvitamin D3 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/47\">",
"     47",
"    </a>",
"    ]. A role for this receptor in humans is suggested by the finding that the genetic locus for the vitamin D receptor has been linked to the occurrence of at least one stone episode in a large cohort of French Canadians, but this has not been confirmed and other studies are needed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Hyperoxaluria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of calcium oxalate stone formation increases as urine oxalate excretion increases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/22\">",
"     22",
"    </a>",
"    ]. It was believed that a small increase in oxalate excretion represented a relatively large percentage change and, therefore, was more likely to promote calcium oxalate precipitation to a greater degree than a similar absolute increase in calcium excretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/49,50\">",
"     49,50",
"    </a>",
"    ], but this has been questioned. The reported frequency of hyperoxaluria varies widely depending upon the gender and number of previous stones in the population studied (",
"    <a class=\"graphic graphic_table graphicRef78303 \" href=\"mobipreview.htm?1/35/1596\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The standard definition of normal urinary oxalate excretion is less than 45",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (0.5",
"    <span class=\"nowrap\">",
"     mmol/day),",
"    </span>",
"    generally less than 20 percent that of calcium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/51\">",
"     51",
"    </a>",
"    ]. However, similar limitations of the chosen \"normal\" cutpoint also apply to oxalate. In fact, the risk of stone formation begins to increase significantly at urinary oxalate excretion above 25",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    well within the \"normal\" range [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relative contribution of endogenous and exogenous oxalate to urine oxalate excretion remains uncertain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/50,52\">",
"     50,52",
"    </a>",
"    ]. Although there is general agreement that increasing dietary oxalate increases urinary oxalate excretion, the amount of the increase varies substantially by the type of food (not just the oxalate content of the food); the impact of dietary oxalate on stone risk appears to be relatively small [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/50,53\">",
"     50,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Endogenous oxalate is primarily derived from the metabolism of glycine and ascorbic acid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/51\">",
"     51",
"    </a>",
"    ]. The actual contribution of dietary oxalate to urinary oxalate excretion has been difficult to ascertain, given incomplete information on the oxalate content and bioavailability in many foods. Dietary oxalate may have a more prominent effect in individuals with idiopathic calcium oxalate nephrolithiasis; these individuals seem to have a higher rate of oxalate absorption (and urinary excretion) than control patients given the same standard diet and amount of exogenous oxalate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of intestinal oxalate absorption is supported by observations regarding the effect of dietary calcium. Dietary calcium can decrease oxalate absorption in the gut by the formation of insoluble calcium oxalate salts in the intestinal lumen. When less calcium is available in the intestinal lumen to bind oxalate, oxalate absorption and therefore urinary oxalate excretion increase. Relatively common settings in which this occurs include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With a low calcium diet, which is generally not recommended for idiopathic calcium stones [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/34\">",
"       34",
"      </a>",
"      ]&nbsp;(see",
"      <a class=\"local\" href=\"#H18\">",
"       'Calcium'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      With increased intestinal calcium absorption as seen in hypercalciuria",
"     </li>",
"     <li>",
"      Malabsorption syndromes, as with small bowel disease (eg, Crohn's disease), surgical bowel resection or diversion, including jejunoileal bypass for obesity (bariatric surgery), or cystic fibrosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/55-62\">",
"       55-62",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This last situation leads to the malabsorption of fatty acids and bile salts, and is called enteric hyperoxaluria. The increase in oxalate absorption and subsequent excretion is due both to binding of free calcium to fatty acids in the intestinal lumen and to increased colonic permeability to small molecules such as oxalate induced by exposure of the colon to nonabsorbed bile salts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/63-65\">",
"     63-65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with malabsorption may have additional factors predisposing to stone formation other than increased oxalate excretion (which can be as high as 80 to 200 mg [0.9 to 2.2 mmol] per day) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. The diarrheal fluid losses can lead both to a reduction in urine volume and, if the patient has a metabolic acidosis, a low urine pH and a marked decrease in citrate excretion (see below); these changes can promote uric acid as well as calcium oxalate stone formation.",
"   </p>",
"   <p>",
"    The net effect in patients with partial ileal bypass for severe hyperlipidemia or obesity is that the incidence of kidney stones may be as high as 4 percent per year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/56,65\">",
"     56,65",
"    </a>",
"    ]. The rate of hyperoxaluric stone formation will no doubt increase given the popularity of modern bariatric surgery. In a series of 132 patients with nephrolithiasis who had undergone modern bariatric surgery, the average time to formation of the first stone was 3.6 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/61\">",
"     61",
"    </a>",
"    ]. Acute or chronic renal failure due to intratubular or interstitial calcium oxalate precipitation also can occur, especially in the setting of volume depletion and decreased urinary flow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/4,67\">",
"     4,67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The magnitude of the increase in oxalate excretion was evaluated in the previously mentioned series of 132 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/61\">",
"     61",
"    </a>",
"    ]. Mean oxalate excretion was 83",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in these patients who underwent modern bariatric surgery (principally Roux-en-Y gastric bypass), which was significantly higher than in routine kidney stone formers or normal subjects (39 and 34",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    respectively), but lower than that in patients who had undergone jejunoileal bypass (103",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    which has been discontinued because of the high rate of nephrolithiasis, renal failure, and other serious complications. In contrast, a study of 18 patients who underwent restrictive bariatric procedures (gastric banding or sleeve gastrectomy) and 54 patients who underwent Roux-en-Y gastric bypass showed significantly lower 24-hour urinary oxalate excretion with restrictive procedures (35 versus 61 mg), suggesting that stone risk might be lower with these newer techniques [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/68\">",
"     68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/31/33274?source=see_link&amp;anchor=H29#H29\">",
"     \"Surgical management of severe obesity\", section on 'Jejunoileal bypass'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reversal of the jejunoileal bypass for control of complications may prevent further deterioration of renal function since it normalizes urinary oxalate excretion. However, it does not completely normalize urinary citrate excretion, resulting in a persistent increase in stone risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/57,58,69\">",
"     57,58,69",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/58/41898?source=see_link\">",
"     \"Complications of bariatric surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Alterations in gastrointestinal flora, such as may be seen with prolonged administration of antibiotics (common in disorders such as cystic fibrosis) can lead to decreased degradation of oxalate, and thus increase the risk of hyperoxaluria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/66,70,71\">",
"     66,70,71",
"    </a>",
"    ]. One possibility is the loss of the bacterium, Oxalobacter formigenes, which degrades oxalate and promotes enteric oxalate secretion (thus reducing urinary oxalate excretion) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/72-75\">",
"     72-75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Administration of a lactic acid bacteria mixture transiently reduced urinary oxalate excretion in patients with hyperoxaluria due to malabsorption syndromes; the mechanism and potential clinical benefit are unknown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, it has been proposed that mild hyperoxaluria may be due to a genetic abnormality (with autosomal dominant inheritance) characterized by increased activity of a",
"    <span class=\"nowrap\">",
"     chloride/oxalate",
"    </span>",
"    anion exchanger (similar to the band 3 protein,",
"    <span class=\"nowrap\">",
"     chloride/bicarbonate",
"    </span>",
"    exchanger in the red cell). This abnormality has been demonstrated in red cells and is associated with increased fractional oxalate excretion, suggesting that it is also present in the renal tubules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/49\">",
"     49",
"    </a>",
"    ]. Another possibility suggested by an experimental model is a defect in oxalate secretion into the intestinal lumen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Higher oxalate production may contribute to the risk of calcium oxalate stone formation, but the mechanisms are unclear. Higher oxalate production is a likely contributor to the higher risk of stone disease in men compared with women. In contrast, dramatically increased oxalate production can occur in certain other settings.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oxalate excretion is markedly enhanced (up to 100 to 300",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      or 1.1 to 3.3",
"      <span class=\"nowrap\">",
"       mmol/day)",
"      </span>",
"      in primary hyperoxaluria, a rare disorder in which enzyme deficiencies lead to overproduction of oxalate from glyoxylate. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/55/12154?source=see_link\">",
"       \"Primary hyperoxaluria\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      High-dose vitamin C therapy may also result in increased oxalate generation as the vitamin C (ascorbic acid) is metabolized [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/78,79\">",
"       78,79",
"      </a>",
"      ]. A study in stone formers estimated that urinary oxalate excretion increases 6 to 13",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for every 1000 mg of vitamin C ingested above 500",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/78\">",
"       78",
"      </a>",
"      ]. Subsequent metabolic studies have demonstrated that the ingestion of 2000",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of vitamin C significantly increases urinary oxalate excretion in a large proportion of calcium oxalate stone-formers as well as normal controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/80,81\">",
"       80,81",
"      </a>",
"      ]. Two observational studies in men reported an increase in stone risk related to self-reported ingestion of larger amounts of vitamin C [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/82,83\">",
"       82,83",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Most investigators recommend limiting the intake of vitamin C to the recommended dietary allowance (90",
"      <span class=\"nowrap\">",
"       mg/d)",
"      </span>",
"      among patients with a history of calcium oxalate stones [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/80,84\">",
"       80,84",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Hypocitraturia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A decrease in excretion of urinary inhibitors of crystal formation is another mechanism that can promote the development of kidney stones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/15,85-88\">",
"     15,85-88",
"    </a>",
"    ]. One substance thought to be a principal inhibitor of stone formation is citrate. Hypocitraturia can occur in isolation in stone formers or in combination with other urinary abnormalities including high urine calcium and high urine oxalate. Hypocitraturia has been defined as citrate excretion below 320",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    but as with all urinary factors, this definition is somewhat arbitrary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/22\">",
"     22",
"    </a>",
"    ], and the association with risk of stone formation is continuous [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Citrate acts in the tubular lumen by combining with calcium to form a nondissociable but soluble complex. As a result, there is less free calcium available to combine with oxalate. In addition, citrate also appears to inhibit the important process of crystal agglomeration, in which individual calcium oxalate crystals combine to form a stone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/89\">",
"     89",
"    </a>",
"    ]. Data suggest that hypocitraturia may also have a genetic basis, as there is a direct association between polymorphisms of the renal sodium-citrate cotransporter gene and urinary citrate excretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One major factor that can limit citrate excretion (by enhancing proximal reabsorption) is chronic metabolic acidosis induced by chronic diarrhea, renal tubular acidosis (complete or incomplete), the administration of carbonic anhydrase inhibitors (including antiepileptic drugs such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/2/10279?source=see_link\">",
"     zonisamide",
"    </a>",
"    ), or ureteral diversion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/26/23973?source=see_link\">",
"     \"Nephrolithiasis in renal tubular acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A fall in citrate excretion can also be induced by a high animal protein diet, a setting in which acid generation is enhanced (",
"    <a class=\"graphic graphic_figure graphicRef56597 \" href=\"mobipreview.htm?24/29/25053\">",
"     figure 1",
"    </a>",
"    ). High protein diets, still popular for weight loss, can have substantial adverse effects on urine citrate. Similarly, a diet low in fruits may result in low urinary potassium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/91\">",
"     91",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Protein'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H20\">",
"     'Potassium'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In incomplete distal (type 1) renal tubular acidosis, a disorder that might actually represent a primary proximal tubular defect, hypocitraturia might occur in the absence of overt metabolic acidosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/92\">",
"     92",
"    </a>",
"    ]. There are no studies establishing the frequency of incomplete distal (type 1) RTA in this setting. This disorder should be suspected if the urine pH is persistently above 5.3 along with low or low-normal serum total CO",
"    <sub>",
"     2",
"    </sub>",
"    ; the diagnosis is confirmed by the lack of acidification of the urine after an",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/52/25411?source=see_link\">",
"     ammonium chloride",
"    </a>",
"    load. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/44/18120?source=see_link\">",
"     \"Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other contributing factors to stone formation in distal (type 1) RTA include hypercalciuria and the persistently high urine pH (usually above 6.0) which promotes the precipitation of calcium phosphate salts; in comparison, calcium oxalate solubility is relatively insensitive to pH. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/26/23973?source=see_link\">",
"     \"Nephrolithiasis in renal tubular acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Normal urine also contains other inhibitors of stone formation, including glycoproteins that are secreted by the tubular epithelial cells such as Tamm-Horsfall mucoprotein (also called uromodulin, which is produced in the thick ascending limb of the loop of Henle), nephrocalcin, and uropontin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/4,93-96\">",
"     4,93-96",
"    </a>",
"    ]. As an example, a marked increase in spontaneous and inducible renal calcium crystals was observed in Tamm-Horsfall mucoprotein-knockout mice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/97\">",
"     97",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/10/9378?source=see_link\">",
"     \"Chapter 4D: Tamm-Horsfall mucoprotein\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Production of chemically abnormal inhibitors, such as Tamm-Horsfall mucoprotein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/94\">",
"     94",
"    </a>",
"    ], and the presence of promotors of crystal aggregation, such as hydroxyapatite [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/98\">",
"     98",
"    </a>",
"    ], may play a contributory role in some recurrent stone-formers. Furthermore, part of the inhibitory effect of urinary citrate may be mediated via an interaction with abnormal Tamm-Horsfall mucoprotein, increasing its ability to impair crystal aggregation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/94\">",
"     94",
"    </a>",
"    ]. However, the clinical importance of protein inhibitors has not been established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Hyperuricosuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past, a higher urine uric acid had been considered to promote calcium oxalate stone formation. One proposed mechanism was that uric acid crystals formed a nidus for subsequent calcium oxalate precipitation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/4\">",
"     4",
"    </a>",
"    ]. Support for the role of hyperuricosuria came from a randomized controlled trial in which",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    significantly reduced the likelihood of calcium oxalate stone recurrence in calcium-stone formers with hyperuricosuria but normal urinary calcium excretion (0.12 versus 0.26 calculus events per year with placebo) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/99\">",
"     99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the role of uric acid in calcium oxalate stone formation remains unproven. In the cross-sectional observational study of 3350 men and women (2237 with a history of nephrolithiasis), mean 24-hour uric acid excretion did not differ between stone formers and controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/22\">",
"     22",
"    </a>",
"    ]. Multivariate adjustment for other urinary factors revealed a significant inverse association between uric acid excretion and the likelihood of being a stone former in men and marginally in younger women. In contrast, the expected associations with hypercalciuria, hyperoxaluria, and hypocitraturia were found.",
"   </p>",
"   <p>",
"    These observations suggest that hyperuricosuria may not be a risk factor for calcium stone formation and that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    may lower the risk of stone formation through a mechanism other than lowering uric acid excretion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Medullary sponge kidney",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of calcium stone formation is markedly increased in medullary sponge kidney, particularly in patients with predisposing metabolic factors such as hypercalciuria or hypocitraturia. Among calcium stone-formers, it is estimated that this disorder is present in 12 to 20 percent overall and 20 to 30 percent of women or patients under age 20 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/100,101\">",
"     100,101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is unclear whether the anatomic changes somehow cause the metabolic disturbances (eg high urine calcium, low urine citrate), or whether their predisposition to nephrocalcinosis (and the interstitial deposition of calcium phosphate) increases the likelihood of nephrolithiasis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/21/37206?source=see_link\">",
"     \"Medullary sponge kidney\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Family history",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relationship between family history and risk of kidney stone formation was assessed in 38,000 men in the Health Professionals Follow-up Study in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/102\">",
"     102",
"    </a>",
"    ]. Over an eight-year period, individuals with a positive family history had a relative risk of 2.6 of experiencing a stone as compared with those without such a history. Higher familial risk has also been noted in Italy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Family history data do not distinguish between genetic and environmental factors. However, there is evidence of genetic susceptibility to the development of calcium stone disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/102,104,105\">",
"     102,104,105",
"    </a>",
"    ]. Most investigators believe that multiple loci are involved, perhaps affecting calcium absorption, resorption and excretion, oxalate absorption, and citrate absorption and excretion. Specific genes that might be involved include the calcium sensing receptor, tight junction proteins, calcium channels in the intestine and kidney, vitamin D receptor, phosphate transporters, and oxalate exchangers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/31,105-108\">",
"     31,105-108",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further support for genetic influences undergoing nephrolithiasis was provided by a twin study from the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/109\">",
"     109",
"    </a>",
"    ]. Concordance rates for a history of renal stones were compared in monozygotic and dizygotic twins among approximately 7500 male-male twin pairs. Based upon the differences in proband rates, the heritability of stone risk was calculated to be approximately 50 percent.",
"   </p>",
"   <p>",
"    Much less common is Dent's disease in which an X-linked recessive defect in an outwardly rectifying chloride channel leads to hypophosphatemia and hypercalciuria. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/45/21209?source=see_link&amp;anchor=H15#H15\">",
"     \"Hereditary hypophosphatemic rickets and tumor-induced osteomalacia\", section on 'Hypophosphatemia with hypercalciuria'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of medical conditions have been associated with an increased risk of stone formation including hypertension, gout, diabetes mellitus, obesity, and weight gain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/110-116\">",
"     110-116",
"    </a>",
"    ], suggesting that nephrolithiasis should be considered a systemic disorder.",
"   </p>",
"   <p>",
"    The risk in patients with diabetes may be related in part to increased urinary calcium excretion, as well as low urinary pH predisposing to uric acid nephrolithiasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/117,118\">",
"     117,118",
"    </a>",
"    ]. The mechanism of increased risk due to obesity is unknown, but may be related to higher uric acid excretion and lower urinary pH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/119,120\">",
"     119,120",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/62/3047?source=see_link\">",
"     \"Uric acid nephrolithiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, patients with urinary tract infections are at increased risk. Betel quid chewing, a common practice in Southeast Asia, has also been associated with calcium oxalate and calcium phosphate kidney stones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/121\">",
"     121",
"    </a>",
"    ]. Certain drugs, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/60/43973?source=see_link\">",
"     triamterene",
"    </a>",
"    , can precipitate and form stones. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/18/39201?source=see_link&amp;anchor=H3#H3\">",
"     \"Triamterene nephrotoxicity\", section on 'Triamterene stones'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DIETARY RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dietary factors can play an important role in promoting stone formation, primarily by affecting the composition of the urine. Studies over the past decade suggest that the importance of specific dietary risk factors varies by age and gender.",
"   </p>",
"   <p>",
"    There are several dietary factors that may play an important role in many patients: fluid, calcium, oxalate, potassium, sodium, animal protein, phytate, sucrose, fructose, and vitamin C intake. Lower intake of fluid, calcium, potassium, and phytate and higher intake of sodium, animal protein, sucrose, fructose, and vitamin C are associated with an increased risk for calcium stone formation. The type of beverage may also influence the risk. The effect of calcium intake is paradoxical, with a decreased risk with increased dietary calcium and an increased or no change in risk with calcium supplements.",
"   </p>",
"   <p>",
"    The combination of dietary factors may also have a significant impact upon stone risk. As an example, the Dietary Approaches to Stop Hypertension (DASH) diet is high in fruits and vegetables, moderate in low-fat dairy products, and low in animal protein. Based upon an analysis of three large cohorts, adherence to a DASH-style diet lowered the risk for kidney stones among men, older women, younger women, high body mass index (BMI) individuals, and low BMI individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/122\">",
"     122",
"    </a>",
"    ]. Thus, the DASH diet is a reasonable option in the attempt to reduce the risk of stone recurrence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Fluid intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;A low fluid intake will lead to a low urine output, thereby promoting stone formation by increasing the concentration of calcium and oxalate (even though the total amount of excretion of these lithogenic factors is not affected). In one report, for example, patients who had a first kidney stone had a baseline daily urine output that was 250 to 350 mL less than controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/123\">",
"     123",
"    </a>",
"    ]. A related concern arises among individuals who work in a very hot environment (with increased insensible losses), in whom the risk of nephrolithiasis is markedly increased without adequate fluid intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of fluid intake on the risk of incident stone formation was illustrated by data from several cohort studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/20,82,104,124\">",
"     20,82,104,124",
"    </a>",
"    ]. In these reports of over 200,000 men and women, there was a 30 percent lower risk of developing symptomatic kidney stones in participants in the highest quintile of fluid intake compared with those in the lowest quintile.",
"   </p>",
"   <p>",
"    In addition to low fluid intake as a risk factor for incident stone disease, increasing fluid intake can lead to a reduction in recurrent stone formation. As an example, a prospective trial randomly assigned 199 patients with a first calcium stone to no therapy or recommendation of a high fluid intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/123\">",
"     123",
"    </a>",
"    ]. At five years, the incidence of new stone formation was significantly lower in the treated patients than in those in the control group (12 versus 27 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Type of fluid",
"    </span>",
"    &nbsp;&mdash;&nbsp;The type of fluid taken in may also be important, although data are sometimes conflicting regarding the effect on urine composition and stone risk. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Grapefruit juice has been associated with an increased risk of stones in epidemiologic studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/125,126\">",
"       125,126",
"      </a>",
"      ]. In the Nurses' Health study, for example, there was a 44 percent increase in risk of stone formation per eight ounce (240 mL) serving per day [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/125\">",
"       125",
"      </a>",
"      ]. Studies examining changes in urinary stone risk factors following ingestion of grapefruit juice (eg, citrate excretion, relative supersaturation of calcium oxalate), were unable to identify a potential mechanism for the observed increase in risk of stone formation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/127-129\">",
"       127-129",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Although data are limited, avoidance of grapefruit and grapefruit juice may be prudent in patients with calcium oxalate stones.",
"     </li>",
"     <li>",
"      Coffee and tea have traditionally been considered to have a high oxalate content. However, some measurements have not found these beverages to be high in oxalate. In fact, consumption of large amounts of tea appears to have a negligible impact on urinary oxalate excretion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/130\">",
"       130",
"      </a>",
"      ]. In prospective studies, higher tea and coffee consumption were associated with a lower risk of stone formation by approximately 10 percent per cup per day [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/125,126\">",
"       125,126",
"      </a>",
"      ]. A study of twins in the United States also found that coffee and perhaps tea were relatively protective [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/109\">",
"       109",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Alcoholic beverages have been purported to increase the risk of stones. However, prospective studies found that beer and wine were associated with a lower risk of stone formation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/125,126,131\">",
"       125,126,131",
"      </a>",
"      ], possibly due to inhibition of ADH release [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/132,133\">",
"       132,133",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Orange juice (which contains both potassium and citrate) was associated with a lower calculated risk of crystal formation (possibly due in part to increased urinary citrate excretion) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/127,134,135\">",
"       127,134,135",
"      </a>",
"      ], but large cohort studies have not found that orange juice independently reduced the likelihood of stone formation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/125,126\">",
"       125,126",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cranberry juice, advocated as prophylaxis against recurrent urinary tract infections, has been variably reported to increase and decrease urinary saturation of calcium oxalate",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      urine pH [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/136-138\">",
"       136-138",
"      </a>",
"      ]. There have been no studies correlating consumption of cranberry juice to actual stone formation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Calcium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ingested calcium is absorbed in the intestines and later excreted in the urine; the proportion absorbed is higher in patients with hypercalciuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/139\">",
"     139",
"    </a>",
"    ]. Although this suggests that a diet high in calcium might promote stone disease, the opposite effect is seen as the risk of stone formation appears to be reduced in both men and women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/19,20,82,104,124\">",
"     19,20,82,104,124",
"    </a>",
"    ]. In contrast, calcium supplements may slightly increase the propensity to form stones, at least in older women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/124,140\">",
"     124,140",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the Nurses' Health Study, a higher dietary calcium intake was associated with a lower incidence of stone disease (multivariate relative risk 0.65 for highest versus lowest quintile of calcium intake) while calcium supplements were associated with a small increase in risk (relative risk 1.2 in supplement users compared with nonusers) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/104\">",
"     104",
"    </a>",
"    ]. The impact of dietary calcium may vary by age. This was suggested in a report from a cohort of men that also found an association between increased dietary calcium and decreased stone formation in men under the age of 60 years, but not in older men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A possible explanation for this phenomenon of contrasting risks depending on the source of calcium is related to the timing of calcium intake, as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dietary sources are ingested with oxalate in foods, binding dietary oxalate in the gut, leading to decreased oxalate absorption and excretion. The fall in oxalate excretion exceeds the rise in calcium excretion; the net effect is a reduction in the relative supersaturation of the urine with respect to calcium oxalate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/139\">",
"       139",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Calcium supplements are often taken in the morning or before bedtime, and not with meals, thus they would not be expected to effectively bind dietary oxalate. This would lead to both maintaining oxalate excretion and, by keeping calcium free in the intestinal lumen, increasing calcium absorption and excretion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is also possible that there may be other inhibitory factors in dairy products, which are the major source of dietary calcium.",
"   </p>",
"   <p>",
"    Some investigators have attempted to categorize individuals based on their pattern of calcium absorption and excretion. In patients classified as having absorptive hypercalciuria, dietary calcium restriction reduced urinary calcium. However, since there would not be a concomitant change in urinary oxalate excretion, there would be a lesser reduction in the relative supersaturation of calcium oxalate, unless perhaps dietary oxalate were also restricted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/141\">",
"     141",
"    </a>",
"    ]. However, evidence is lacking that restriction of dietary calcium reduces the rate of stone formation in these patients, and there is substantial evidence that reducing dietary calcium intake could be harmful; thus, dietary calcium restriction is not recommended.",
"   </p>",
"   <p>",
"    An understanding of all of these factors is essential for the appropriate evaluation and treatment of patients with calcium stone disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/22/29033?source=see_link\">",
"     \"Evaluation of the adult patient with established nephrolithiasis and treatment if stone composition is unknown\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/2/38953?source=see_link\">",
"     \"Prevention of recurrent calcium stones in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Oxalate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oxalate is found in many foods, typically in small amounts. Oxalate is also generated from the metabolism of glycine, hydroxyproline and vitamin C (ascorbic acid). Oxalate absorbed from dietary sources or produced from endogenous metabolism is eventually excreted in the urine. There is continued debate regarding the relative contribution of dietary and endogenously derived oxalate on urinary oxalate; it has been estimated that 10 to 50 percent of urinary oxalate is derived from dietary oxalate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Difficulties in measuring the oxalate content of individual foods has previously led to unreliable information. Reliable assays now exist for direct determination of oxalate in foods [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/50,142,143\">",
"     50,142,143",
"    </a>",
"    ]. There is currently a list of more than 200 foods analyzed with more modern methods, which can be downloaded from the following web address:",
"    <a class=\"external\" href=\"https://regepi.bwh.harvard.edu/health/nutrition.html\">",
"     https://regepi.bwh.harvard.edu/health/nutrition.html",
"    </a>",
"    . The lack of information on food oxalate content has previously hindered efforts to examine the impact of dietary oxalate on stone formation.",
"   </p>",
"   <p>",
"    To examine the relationship between stone risk and oxalate intake, a prospective study was performed based upon food frequency questionnaires of three large cohorts: the Health Professionals follow-up study and the Nurse's Health Studies I and II [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/53\">",
"     53",
"    </a>",
"    ]. When individuals in the highest quintile for dietary oxalate intake were compared to the lowest quintile, there was a mild increase in the risk of stones for men (RR of 1.22, 95% CI 1.03-1.45) and for older women (RR of 1.21, 95% CI 1.01-1.44). This risk was higher in men with a decreased dietary intake of calcium. In addition, eight or more servings of spinach per month (which accounted for &gt;40 percent of oxalate intake) compared with fewer than one serving per month was associated with a similar increase in stone risk for older men and women. In contrast, dietary oxalate and spinach intake were not associated with an increased risk for younger women. Thus, dietary oxalate intake is only a modest risk factor for incident kidney stones.",
"   </p>",
"   <p>",
"    Dietary intervention studies have also demonstrated that higher oxalate intake increases urinary oxalate and presumably increases the risk of stone formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/144\">",
"     144",
"    </a>",
"    ]. However, other factors also need to be considered, such as higher intake of calcium and magnesium, which may reduce the absorption of dietary oxalate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/145,146\">",
"     145,146",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Hyperoxaluria'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Nevertheless, because the risk of stone formation increases with increasing urinary oxalate, a lower intake of dietary oxalate and vitamin C seems prudent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/22\">",
"     22",
"    </a>",
"    ]. The challenge remains how to choose a low oxalate diet without inappropriately restricting intake of fruits and vegetables. Aggressive restriction of dietary oxalate is not practical. Follow-up 24-hour urine oxalate measurements should be used to determine if the dietary oxalate restriction is beneficial; if not, then it should be discontinued.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Potassium",
"    </span>",
"    &nbsp;&mdash;&nbsp;A higher dietary potassium intake substantially reduced the risk of incident stone formation in men and older women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/20,82,104\">",
"     20,82,104",
"    </a>",
"    ], but not in younger women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/124\">",
"     124",
"    </a>",
"    ]. One possible explanation is that higher potassium intake may reduce the risk of stone formation by reducing urinary calcium excretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/147\">",
"     147",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another mechanism is that higher potassium intake may increase urinary citrate excretion (since potassium-rich foods tend to have a high alkali content) thereby increasing the inhibitory properties of urine. Foods that are rich in potassium include fruits and vegetables. Although some have recommended a reduction in the intake of certain fruits and vegetables with the hope this would reduce oxalate intake and excretion, other studies found a slight protective effect of fruit ingestion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/91,109\">",
"     91,109",
"    </a>",
"    ]. Overall, given that dietary potassium is associated with a lower risk and fruits and vegetables are a major source of dietary potassium, it seems that there is evidence to encourage intake of fruits and vegetables.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Sodium",
"    </span>",
"    &nbsp;&mdash;&nbsp;A high sodium intake will enhance the excretion of calcium, a relationship that has been thought to be due in part to the reabsorption of calcium passively following that of sodium and water in the proximal tubule [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/148\">",
"     148",
"    </a>",
"    ]. Thus, the decrease in proximal sodium reabsorption induced by volume expansion will lead to a parallel reduction in calcium transport and increased calcium excretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/149,150\">",
"     149,150",
"    </a>",
"    ]. In one study of stone formers with idiopathic hypercalciuria, for example, increasing sodium intake from 80 to 200",
"    <span class=\"nowrap\">",
"     meq/day",
"    </span>",
"    led to almost a 40 percent rise in calcium excretion (from 278 to 384",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [or 7 to 9.5",
"    <span class=\"nowrap\">",
"     mmol/day])",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/149\">",
"     149",
"    </a>",
"    ]. This increase in calcium excretion may result in negative calcium balance, which would promote the development of osteopenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A high sodium diet may also produce an undesirable reduction in citrate excretion via an uncertain mechanism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/150\">",
"     150",
"    </a>",
"    ]. In addition, the anion accompanying sodium appears to be a determinant of the effect on calcium excretion. In particular, chloride seems to be required for the calciuresis to occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/150\">",
"     150",
"    </a>",
"    ]. How chloride acts in this setting is not clear.",
"   </p>",
"   <p>",
"    The clinical magnitude of these effects on stone formation is not clear. The Nurses' Health Study noted a relative risk of 1.30 for symptomatic stones in women in the highest quintile of sodium intake compared with those in the lowest quintile [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/104\">",
"     104",
"    </a>",
"    ]. No association was seen in men or younger women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/20,82,124\">",
"     20,82,124",
"    </a>",
"    ], although the lack of an association may be due to the difficulty in accurately assessing sodium intake by questionnaires. In the study of over 3300 individuals with 24-hour urine collections, urine sodium excretion was not independently associated with likelihood of being a stone former [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/22\">",
"     22",
"    </a>",
"    ], but these analyses were adjusted for calcium and citrate (the potential factors through which sodium may act). In the Women's Health Initiative, the risk of stone formation was 61 percent higher among women in the highest quintile of sodium intake compared with the lowest quintile [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/151\">",
"     151",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Protein",
"    </span>",
"    &nbsp;&mdash;&nbsp;A high animal protein intake has been associated with an increased incidence of stone disease, at least in men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/20\">",
"     20",
"    </a>",
"    ]. Potentially important factors in relation to animal protein intake are the acid generated from the metabolism of sulfur-containing amino acids and the uric acid generated from the metabolism of purines.",
"   </p>",
"   <p>",
"    The net effect of dietary protein is several changes in urinary composition that could promote calcium stone formation, including an increase in urine calcium excretion and a decrease in urine citrate (",
"    <a class=\"graphic graphic_figure graphicRef56597 \" href=\"mobipreview.htm?24/29/25053\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/106,152-154\">",
"     106,152-154",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A rise in urinary calcium excretion due primarily to the release of calcium from bone following buffering of some of the hydrogen ions by bone salts [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/106,152-154\">",
"       106,152-154",
"      </a>",
"      ]. Although a high-protein diet can contribute, it is not likely to be the sole cause of the increased calcium excretion in idiopathic hypercalciuria. When compared to normals, these patients have increased calcium excretion in relation to sulfate excretion (which is used as a marker for the metabolism of sulfur-containing amino acids) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A reduction in citrate excretion due to enhanced proximal citrate reabsorption [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/106,152,155\">",
"       106,152,155",
"      </a>",
"      ]. This effect is induced at least in part by the fall in tubular fluid pH resulting from the acid load. The increased availability of hydrogen ions will convert the trivalent citrate anion into the divalent anion, which is more easily reabsorbed via the sodium-citrate cotransporter in the luminal membrane [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/155\">",
"       155",
"      </a>",
"      ]. The associated fall in intracellular pH also may contribute by increasing cell citrate utilization [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/156\">",
"       156",
"      </a>",
"      ]; the ensuing reduction in cell citrate levels favors passive citrate entry from the tubular lumen into the cell.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, neutralizing the acid load associated with high protein diet does",
"    <strong>",
"     not",
"    </strong>",
"    ameliorate hypercalciuria. This was shown in a crossover study of 11 healthy adults fed a normal or high protein diet in combination with either potassium citrate (an alkaline salt) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/57/34711?source=see_link\">",
"     potassium chloride",
"    </a>",
"    (a neutral salt) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/157\">",
"     157",
"    </a>",
"    ]. Although supplementation with potassium citrate both prevented the fall in urinary citrate excretion associated with the high protein diet and completely neutralized the acid load, the high protein diet still produced a significant increase in urinary calcium excretion.",
"   </p>",
"   <p>",
"    Thus, the hypercalciuria resulting from a high protein diet cannot be explained by the associated acid load. The mechanism for the short-term effect of a high protein diet is unclear. Long-term, a high protein diet may produce hypercalciuria by increasing renal calcitriol production that may be mediated by an increase in renal mass [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/158\">",
"     158",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These changes in urinary composition are primarily seen with a high intake of animal protein. Vegetable protein has a much lesser effect on calcium, uric acid, and citrate excretion, since it has a lower sulfur content and therefore generates less acid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/153\">",
"     153",
"    </a>",
"    ]. Protein intake also has a limited and unpredictable effect on oxalate excretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/159\">",
"     159",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In prospective observational studies, animal protein intake was associated with a higher risk of incident stone formation in men, but only among those with BMI &lt;25",
"    <span class=\"nowrap\">",
"     kg/m2",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/82\">",
"     82",
"    </a>",
"    ]. No increased risk has been observed in women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/104,124\">",
"     104,124",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Phytate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased amounts of dietary phytate may lower the risk of stone formation. In a study of nearly 100,000 younger female participants in the Nurses Health Study II, the adjusted relative risk of stone formation among those in the highest quintile of phytate intake, compared to those in the lowest, was 0.63 (95% CI 0.51-0.78) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/124\">",
"     124",
"    </a>",
"    ]. Although its mechanism of action is unclear, calcium oxalate crystal formation is strongly inhibited in vitro by phytate. The principal dietary sources of phytate in this population were cold cereal, dark bread, and beans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Sucrose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Higher sucrose intake is associated with an increased risk of stone formation in younger and older women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/104,124\">",
"     104,124",
"    </a>",
"    ]. Nearly 40 years ago, Lemann showed that an oral glucose load increased urine calcium excretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/160\">",
"     160",
"    </a>",
"    ]. Although the mechanism is unknown, higher insulin levels may lead to higher urinary calcium excretion; however, some data are contradictory [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/161\">",
"     161",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     PREVALENCE OF URINARY RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The degree to which the above risk factors contribute to stone disease varies in different populations. In addition, the definitions of \"abnormal\" are somewhat arbitrary and may differ from study to study.",
"   </p>",
"   <p>",
"    One study evaluated 1270 patients in Texas over a 15-year period for recurrent stone disease and reported their frequencies of urinary abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/162\">",
"     162",
"    </a>",
"    ]. Many patients had more than one risk factor.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hypercalciuria &mdash; 61 percent, including some patients with primary hyperparathyroidism",
"     </li>",
"     <li>",
"      Hyperuricosuric calcium stones &mdash; 36 percent",
"     </li>",
"     <li>",
"      Hypocitraturia &mdash; 28 percent idiopathic and 3.3 percent due to distal (type 1) renal tubular acidosis or chronic diarrhea",
"     </li>",
"     <li>",
"      Hyperoxaluria &mdash; 8 percent, including enteric and primary forms and markedly increased oxalate intake",
"     </li>",
"     <li>",
"      Low urine volume (&lt;1",
"      <span class=\"nowrap\">",
"       L/day)",
"      </span>",
"      &mdash; 15 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another report compared the frequency of these biochemical abnormalities in first time stone formers and in normal subjects, and a substantial difference was noted only for urinary calcium and citrate excretion (",
"    <a class=\"graphic graphic_table graphicRef67319 \" href=\"mobipreview.htm?30/63/31739\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/53/33626/abstract/163\">",
"     163",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/53/28499?source=see_link\">",
"       \"Patient information: Kidney stones in adults (Beyond the Basics)\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eighty percent of patients with nephrolithiasis form calcium stones, most of which are composed primarily of calcium oxalate or, less often, calcium phosphate. A large number of metabolic, anatomic, and dietary factors may contribute to the development of calcium stones.",
"   </p>",
"   <p>",
"    The principal risk factors are (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Risk factors'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Higher urine calcium",
"     </li>",
"     <li>",
"      Higher urine oxalate",
"     </li>",
"     <li>",
"      Lower urine citrate",
"     </li>",
"     <li>",
"      Lower urine volume",
"     </li>",
"     <li>",
"      Dietary factors, including a low intake of fluid, calcium, potassium and phytate, and a high intake of oxalate, sodium, sucrose, fructose, and animal protein",
"     </li>",
"     <li>",
"      Medical conditions, including primary hyperparathyroidism, obesity, gout, diabetes, and medullary sponge kidney",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The degree to which the above risk factors contribute to stone disease varies in different populations. It is also important to realize that the definitions of \"abnormal\" are somewhat arbitrary, and that the risk of stone formation begins to increase even in what has been traditionally considered the \"normal\" range.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/1\">",
"      Johnson CM, Wilson DM, O'Fallon WM, et al. Renal stone epidemiology: a 25-year study in Rochester, Minnesota. Kidney Int 1979; 16:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/2\">",
"      Stamatelou KK, Francis ME, Jones CA, et al. Time trends in reported prevalence of kidney stones in the United States: 1976-1994. Kidney Int 2003; 63:1817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/3\">",
"      Lieske JC, Pe&ntilde;a de la Vega LS, Slezak JM, et al. Renal stone epidemiology in Rochester, Minnesota: an update. Kidney Int 2006; 69:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/4\">",
"      Coe FL, Parks JH, Asplin JR. The pathogenesis and treatment of kidney stones. N Engl J Med 1992; 327:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/5\">",
"      Robertson WG, Peacock M. Calcium oxalate crystalluria and inhibitors of crystallization in recurrent renal stone-formers. Clin Sci 1972; 43:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/6\">",
"      Kumar V, Pe&ntilde;a de la Vega L, Farell G, Lieske JC. Urinary macromolecular inhibition of crystal adhesion to renal epithelial cells is impaired in male stone formers. Kidney Int 2005; 68:1784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/7\">",
"      Sheng X, Ward MD, Wesson JA. Crystal surface adhesion explains the pathological activity of calcium oxalate hydrates in kidney stone formation. J Am Soc Nephrol 2005; 16:1904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/8\">",
"      Kok DJ, Khan SR. Calcium oxalate nephrolithiasis, a free or fixed particle disease. Kidney Int 1994; 46:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/9\">",
"      Asselman M, Verhulst A, De Broe ME, Verkoelen CF. Calcium oxalate crystal adherence to hyaluronan-, osteopontin-, and CD44-expressing injured/regenerating tubular epithelial cells in rat kidneys. J Am Soc Nephrol 2003; 14:3155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/10\">",
"      Evan AP, Lingeman JE, Coe FL, et al. Randall's plaque of patients with nephrolithiasis begins in basement membranes of thin loops of Henle. J Clin Invest 2003; 111:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/11\">",
"      Evan AP, Coe FL, Rittling SR, et al. Apatite plaque particles in inner medulla of kidneys of calcium oxalate stone formers: osteopontin localization. Kidney Int 2005; 68:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/12\">",
"      Evan A, Lingeman J, Coe FL, Worcester E. Randall's plaque: pathogenesis and role in calcium oxalate nephrolithiasis. Kidney Int 2006; 69:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/13\">",
"      Matlaga BR, Williams JC Jr, Kim SC, et al. Endoscopic evidence of calculus attachment to Randall's plaque. J Urol 2006; 175:1720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/14\">",
"      Evan AP, Lingeman JE, Worcester EM, et al. Renal histopathology and crystal deposits in patients with small bowel resection and calcium oxalate stone disease. Kidney Int 2010; 78:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/15\">",
"      Parks JH, Coe FL. A urinary calcium-citrate index for the evaluation of nephrolithiasis. Kidney Int 1986; 30:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/16\">",
"      Bihl G, Meyers A. Recurrent renal stone disease-advances in pathogenesis and clinical management. Lancet 2001; 358:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/17\">",
"      Atan L, Andreoni C, Ortiz V, et al. High kidney stone risk in men working in steel industry at hot temperatures. Urology 2005; 65:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/18\">",
"      Coe FL, Evan A, Worcester E. Kidney stone disease. J Clin Invest 2005; 115:2598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/19\">",
"      Borghi L, Schianchi T, Meschi T, et al. Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. N Engl J Med 2002; 346:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/20\">",
"      Curhan GC, Willett WC, Rimm EB, Stampfer MJ. A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. N Engl J Med 1993; 328:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/21\">",
"      Gault MH, Chafe LL, Morgan JM, et al. Comparison of patients with idiopathic calcium phosphate and calcium oxalate stones. Medicine (Baltimore) 1991; 70:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/22\">",
"      Curhan GC, Taylor EN. 24-h uric acid excretion and the risk of kidney stones. Kidney Int 2008; 73:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/23\">",
"      Trinchieri A, Rovera F, Nespoli R, Curr&ograve; A. Clinical observations on 2086 patients with upper urinary tract stone. Arch Ital Urol Androl 1996; 68:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/24\">",
"      Corbetta S, Baccarelli A, Aroldi A, et al. Risk factors associated to kidney stones in primary hyperparathyroidism. J Endocrinol Invest 2005; 28:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/25\">",
"      Pak CY. Etiology and treatment of urolithiasis. Am J Kidney Dis 1991; 18:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/26\">",
"      Frick KK, Bushinsky DA. Molecular mechanisms of primary hypercalciuria. J Am Soc Nephrol 2003; 14:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/27\">",
"      Sorensen MD, Eisner BH, Stone KL, et al. Impact of calcium intake and intestinal calcium absorption on kidney stones in older women: the study of osteoporotic fractures. J Urol 2012; 187:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/28\">",
"      Reed BY, Heller HJ, Gitomer WL, Pak CY. Mapping a gene defect in absorptive hypercalciuria to chromosome 1q23.3-q24. J Clin Endocrinol Metab 1999; 84:3907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/29\">",
"      Wolf MT, Zalewski I, Martin FC, et al. Mapping a new suggestive gene locus for autosomal dominant nephrolithiasis to chromosome 9q33.2-q34.2 by total genome search for linkage. Nephrol Dial Transplant 2005; 20:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/30\">",
"      Gambaro G, Vezzoli G, Casari G, et al. Genetics of hypercalciuria and calcium nephrolithiasis: from the rare monogenic to the common polygenic forms. Am J Kidney Dis 2004; 44:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/31\">",
"      Moe OW, Bonny O. Genetic hypercalciuria. J Am Soc Nephrol 2005; 16:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/32\">",
"      Gudbjartsson DF, Holm H, Indridason OS, et al. Association of variants at UMOD with chronic kidney disease and kidney stones-role of age and comorbid diseases. PLoS Genet 2010; 6:e1001039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/33\">",
"      Vezzoli G, Terranegra A, Arcidiacono T, Soldati L. Genetics and calcium nephrolithiasis. Kidney Int 2011; 80:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/34\">",
"      Bataille P, Achard JM, Fournier A, et al. Diet, vitamin D and vertebral mineral density in hypercalciuric calcium stone formers. Kidney Int 1991; 39:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/35\">",
"      Lemann J Jr, Worcester EM, Gray RW. Hypercalciuria and stones. Am J Kidney Dis 1991; 17:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/36\">",
"      Adams ND, Gray RW, Lemann J Jr, Cheung HS. Effects of calcitriol administration on calcium metabolism healthy men. Kidney Int 1982; 21:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/37\">",
"      Pietschmann F, Breslau NA, Pak CY. Reduced vertebral bone density in hypercalciuric nephrolithiasis. J Bone Miner Res 1992; 7:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/38\">",
"      Martini LA, Cuppari L, Colugnati FA, et al. High sodium chloride intake is associated with low bone density in calcium stone-forming patients. Clin Nephrol 2000; 54:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/39\">",
"      Misael da Silva AM, dos Reis LM, Pereira RC, et al. Bone involvement in idiopathic hypercalciuria. Clin Nephrol 2002; 57:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/40\">",
"      Asplin JR, Bauer KA, Kinder J, et al. Bone mineral density and urine calcium excretion among subjects with and without nephrolithiasis. Kidney Int 2003; 63:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/41\">",
"      Lau YK, Wasserstein A, Westby GR, et al. Proximal tubular defects in idiopathic hypercalciuria: resistance to phosphate administration. Miner Electrolyte Metab 1982; 7:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/42\">",
"      Levi M, Breusegem S, Bruesegem S. Renal phosphate-transporter regulatory proteins and nephrolithiasis. N Engl J Med 2008; 359:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/43\">",
"      Karim Z, G&eacute;rard B, Bakouh N, et al. NHERF1 mutations and responsiveness of renal parathyroid hormone. N Engl J Med 2008; 359:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/44\">",
"      Pri&eacute; D, Beck L, Silve C, Friedlander G. Hypophosphatemia and calcium nephrolithiasis. Nephron Exp Nephrol 2004; 98:e50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/45\">",
"      Rendina D, Mossetti G, De Filippo G, et al. Fibroblast growth factor 23 is increased in calcium nephrolithiasis with hypophosphatemia and renal phosphate leak. J Clin Endocrinol Metab 2006; 91:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/46\">",
"      Alpern RJ, Sakhaee K. Does hyperphosphaturia underlie hypercalciuria? Lancet 1997; 349:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/47\">",
"      Yao J, Kathpalia P, Bushinsky DA, Favus MJ. Hyperresponsiveness of vitamin D receptor gene expression to 1,25-dihydroxyvitamin D3. A new characteristic of genetic hypercalciuric stone-forming rats. J Clin Invest 1998; 101:2223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/48\">",
"      Scott P, Ouimet D, Valiquette L, et al. Suggestive evidence for a susceptibility gene near the vitamin D receptor locus in idiopathic calcium stone formation. J Am Soc Nephrol 1999; 10:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/49\">",
"      Gambaro G, Petrarulo M, Nardelotto A, et al. Erythrocyte transmembrane flux and renal clearance of oxalate in idiopathic calcium nephrolithiasis. Kidney Int 1995; 48:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/50\">",
"      Holmes RP, Goodman HO, Assimos DG. Contribution of dietary oxalate to urinary oxalate excretion. Kidney Int 2001; 59:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/51\">",
"      Smith LH. Diet and hyperoxaluria in the syndrome of idiopathic calcium oxalate urolithiasis. Am J Kidney Dis 1991; 17:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/52\">",
"      Robijn S, Hoppe B, Vervaet BA, et al. Hyperoxaluria: a gut-kidney axis? Kidney Int 2011; 80:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/53\">",
"      Taylor EN, Curhan GC. Oxalate intake and the risk for nephrolithiasis. J Am Soc Nephrol 2007; 18:2198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/54\">",
"      Voss S, Hesse A, Zimmermann DJ, et al. Intestinal oxalate absorption is higher in idiopathic calcium oxalate stone formers than in healthy controls: measurements with the [(13)C2]oxalate absorption test. J Urol 2006; 175:1711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/55\">",
"      Parks JH, Worcester EM, O'Connor RC, Coe FL. Urine stone risk factors in nephrolithiasis patients with and without bowel disease. Kidney Int 2003; 63:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/56\">",
"      Annuk M, Backman U, Holmgren K, Vessby B. Urinary calculi and jejunoileal bypass operation. A long-term follow-up. Scand J Urol Nephrol 1998; 32:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/57\">",
"      Hassan I, Juncos LA, Milliner DS, et al. Chronic renal failure secondary to oxalate nephropathy: a preventable complication after jejunoileal bypass. Mayo Clin Proc 2001; 76:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/58\">",
"      Dhar NB, Grundfest S, Jones JS, Streem SB. Jejunoileal bypass reversal: effect on renal function, metabolic parameters and stone formation. J Urol 2005; 174:1844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/59\">",
"      McConnell N, Campbell S, Gillanders I, et al. Risk factors for developing renal stones in inflammatory bowel disease. BJU Int 2002; 89:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/60\">",
"      Terribile M, Capuano M, Cangiano G, et al. Factors increasing the risk for stone formation in adult patients with cystic fibrosis. Nephrol Dial Transplant 2006; 21:1870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/61\">",
"      Asplin JR, Coe FL. Hyperoxaluria in kidney stone formers treated with modern bariatric surgery. J Urol 2007; 177:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/62\">",
"      Sinha MK, Collazo-Clavell ML, Rule A, et al. Hyperoxaluric nephrolithiasis is a complication of Roux-en-Y gastric bypass surgery. Kidney Int 2007; 72:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/63\">",
"      Williams HE. Oxalic acid and the hyperoxaluric syndromes. Kidney Int 1978; 13:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/64\">",
"      Kathpalia SC, Favus MJ, Coe FL. Evidence for size and charge permselectivity of rat ascending colon. Effects of ricinoleate and bile salts on oxalic acid and neutral sugar transport. J Clin Invest 1984; 74:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/65\">",
"      Obialo CI, Clayman RV, Matts JP, et al. Pathogenesis of nephrolithiasis post-partial ileal bypass surgery: case-control study. The POSCH Group. Kidney Int 1991; 39:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/66\">",
"      Hoppe B, von Unruh GE, Blank G, et al. Absorptive hyperoxaluria leads to an increased risk for urolithiasis or nephrocalcinosis in cystic fibrosis. Am J Kidney Dis 2005; 46:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/67\">",
"      Wharton R, D'Agati V, Magun AM, et al. Acute deterioration of renal function associated with enteric hyperoxaluria. Clin Nephrol 1990; 34:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/68\">",
"      Semins MJ, Asplin JR, Steele K, et al. The effect of restrictive bariatric surgery on urinary stone risk factors. Urology 2010; 76:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/69\">",
"      Patel BN, Passman CM, Fernandez A, et al. Prevalence of hyperoxaluria after bariatric surgery. J Urol 2009; 181:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/70\">",
"      Sidhu H, Hoppe B, Hesse A, et al. Absence of Oxalobacter formigenes in cystic fibrosis patients: a risk factor for hyperoxaluria. Lancet 1998; 352:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/71\">",
"      Mittal RD, Kumar R, Mittal B, et al. Stone composition, metabolic profile and the presence of the gut-inhabiting bacterium Oxalobacter formigenes as risk factors for renal stone formation. Med Princ Pract 2003; 12:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/72\">",
"      Duncan SH, Richardson AJ, Kaul P, et al. Oxalobacter formigenes and its potential role in human health. Appl Environ Microbiol 2002; 68:3841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/73\">",
"      Goldfarb DS. Microorganisms and calcium oxalate stone disease. Nephron Physiol 2004; 98:p48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/74\">",
"      Hatch M, Cornelius J, Allison M, et al. Oxalobacter sp. reduces urinary oxalate excretion by promoting enteric oxalate secretion. Kidney Int 2006; 69:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/75\">",
"      Kaufman DW, Kelly JP, Curhan GC, et al. Oxalobacter formigenes may reduce the risk of calcium oxalate kidney stones. J Am Soc Nephrol 2008; 19:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/76\">",
"      Lieske JC, Goldfarb DS, De Simone C, Regnier C. Use of a probiotic to decrease enteric hyperoxaluria. Kidney Int 2005; 68:1244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/77\">",
"      Jiang Z, Asplin JR, Evan AP, et al. Calcium oxalate urolithiasis in mice lacking anion transporter Slc26a6. Nat Genet 2006; 38:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/78\">",
"      Urivetzky M, Kessaris D, Smith AD. Ascorbic acid overdosing: a risk factor for calcium oxalate nephrolithiasis. J Urol 1992; 147:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/79\">",
"      Baxmann AC, De O G Mendon&ccedil;a C, Heilberg IP. Effect of vitamin C supplements on urinary oxalate and pH in calcium stone-forming patients. Kidney Int 2003; 63:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/80\">",
"      Traxer O, Huet B, Poindexter J, et al. Effect of ascorbic acid consumption on urinary stone risk factors. J Urol 2003; 170:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/81\">",
"      Massey LK, Liebman M, Kynast-Gales SA. Ascorbate increases human oxaluria and kidney stone risk. J Nutr 2005; 135:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/82\">",
"      Taylor EN, Stampfer MJ, Curhan GC. Dietary factors and the risk of incident kidney stones in men: new insights after 14 years of follow-up. J Am Soc Nephrol 2004; 15:3225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/83\">",
"      Thomas LD, Elinder CG, Tiselius HG, et al. Ascorbic Acid supplements and kidney stone incidence among men: a prospective study. JAMA Intern Med 2013; 173:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/84\">",
"      Chai W, Liebman M, Kynast-Gales S, Massey L. Oxalate absorption and endogenous oxalate synthesis from ascorbate in calcium oxalate stone formers and non-stone formers. Am J Kidney Dis 2004; 44:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/85\">",
"      Rudman, D, Kutner, MH, Redd, SC II, et al. Hypocitricuria in calcium nephrolithiasis. J Clin Endocrinol Metab 1982; 55:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/86\">",
"      Asplin JR, Parks JH, Chen MS, et al. Reduced crystallization inhibition by urine from men with nephrolithiasis. Kidney Int 1999; 56:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/87\">",
"      Asplin JR, Parks JH, Nakagawa Y, Coe FL. Reduced crystallization inhibition by urine from women with nephrolithiasis. Kidney Int 2002; 61:1821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/88\">",
"      Wesson JA, Johnson RJ, Mazzali M, et al. Osteopontin is a critical inhibitor of calcium oxalate crystal formation and retention in renal tubules. J Am Soc Nephrol 2003; 14:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/89\">",
"      Kok DJ, Papapoulos SE, Bijvoet OL. Crystal agglomeration is a major element in calcium oxalate urinary stone formation. Kidney Int 1990; 37:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/90\">",
"      Okamoto N, Aruga S, Matsuzaki S, et al. Associations between renal sodium-citrate cotransporter (hNaDC-1) gene polymorphism and urinary citrate excretion in recurrent renal calcium stone formers and normal controls. Int J Urol 2007; 14:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/91\">",
"      Domrongkitchaiporn S, Stitchantrakul W, Kochakarn W. Causes of hypocitraturia in recurrent calcium stone formers: focusing on urinary potassium excretion. Am J Kidney Dis 2006; 48:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/92\">",
"      Donnelly S, Kamel KS, Vasuvattakul S, et al. Might distal renal tubular acidosis be a proximal tubular cell disorder? Am J Kidney Dis 1992; 19:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/93\">",
"      Lieske JC, Toback FG. Regulation of renal epithelial cell endocytosis of calcium oxalate monohydrate crystals. Am J Physiol 1993; 264:F800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/94\">",
"      Hess B, Zipperle L, Jaeger P. Citrate and calcium effects on Tamm-Horsfall glycoprotein as a modifier of calcium oxalate crystal aggregation. Am J Physiol 1993; 265:F784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/95\">",
"      Asplin JR, Arsenault D, Parks JH, et al. Contribution of human uropontin to inhibition of calcium oxalate crystallization. Kidney Int 1998; 53:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/96\">",
"      Min W, Shiraga H, Chalko C, et al. Quantitative studies of human urinary excretion of uropontin. Kidney Int 1998; 53:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/97\">",
"      Mo L, Huang HY, Zhu XH, et al. Tamm-Horsfall protein is a critical renal defense factor protecting against calcium oxalate crystal formation. Kidney Int 2004; 66:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/98\">",
"      Baumann JM, Affolter B, Casella R. Aggregation of freshly precipitated calcium oxalate crystals in urine of calcium stone patients and controls. Urol Res 2011; 39:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/99\">",
"      Ettinger B, Tang A, Citron JT, et al. Randomized trial of allopurinol in the prevention of calcium oxalate calculi. N Engl J Med 1986; 315:1386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/100\">",
"      Yagisawa T, Kobayashi C, Hayashi T, et al. Contributory metabolic factors in the development of nephrolithiasis in patients with medullary sponge kidney. Am J Kidney Dis 2001; 37:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/101\">",
"      Parks JH, Coe FL, Strauss AL. Calcium nephrolithiasis and medullary sponge kidney in women. N Engl J Med 1982; 306:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/102\">",
"      Curhan GC, Willett WC, Rimm EB, Stampfer MJ. Family history and risk of kidney stones. J Am Soc Nephrol 1997; 8:1568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/103\">",
"      Serio A, Fraioli A. Epidemiology of nephrolithiasis. Nephron 1999; 81 Suppl 1:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/104\">",
"      Curhan GC, Willett WC, Speizer FE, et al. Comparison of dietary calcium with supplemental calcium and other nutrients as factors affecting the risk for kidney stones in women. Ann Intern Med 1997; 126:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/105\">",
"      Goodman HO, Holmes RP, Assimos DG. Genetic factors in calcium oxalate stone disease. J Urol 1995; 153:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/106\">",
"      Reddy ST, Wang CY, Sakhaee K, et al. Effect of low-carbohydrate high-protein diets on acid-base balance, stone-forming propensity, and calcium metabolism. Am J Kidney Dis 2002; 40:265.",
"     </a>",
"    </li>",
"    <li>",
"     Tencza, AL, Ichikawa, S, Dang, A, et al. Hypophosphatemic Rickets with Hypercalciuria due to Mutation in SLC34A3/Type IIc Sodium-Phosphate Cotransporter: Presentation as Hypercalciuria and Nephrolithiasis. J Clin Endocrinol Metab; 2009 Oct 9 [Epub ahead of print].",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/108\">",
"      Thorleifsson G, Holm H, Edvardsson V, et al. Sequence variants in the CLDN14 gene associate with kidney stones and bone mineral density. Nat Genet 2009; 41:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/109\">",
"      Goldfarb DS, Fischer ME, Keich Y, Goldberg J. A twin study of genetic and dietary influences on nephrolithiasis: a report from the Vietnam Era Twin (VET) Registry. Kidney Int 2005; 67:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/110\">",
"      Kramer HJ, Choi HK, Atkinson K, et al. The association between gout and nephrolithiasis in men: The Health Professionals' Follow-Up Study. Kidney Int 2003; 64:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/111\">",
"      Kramer HM, Curhan G. The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988-1994. Am J Kidney Dis 2002; 40:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/112\">",
"      Curhan GC, Willett WC, Rimm EB, et al. Body size and risk of kidney stones. J Am Soc Nephrol 1998; 9:1645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/113\">",
"      Taylor EN, Stampfer MJ, Curhan GC. Obesity, weight gain, and the risk of kidney stones. JAMA 2005; 293:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/114\">",
"      Taylor EN, Stampfer MJ, Curhan GC. Diabetes mellitus and the risk of nephrolithiasis. Kidney Int 2005; 68:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/115\">",
"      Daudon M, Lacour B, Jungers P. Influence of body size on urinary stone composition in men and women. Urol Res 2006; 34:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/116\">",
"      Sarica K, Altay B, Erturhan S. Effect of being overweight on stone-forming risk factors. Urology 2008; 71:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/117\">",
"      Cameron MA, Maalouf NM, Adams-Huet B, et al. Urine composition in type 2 diabetes: predisposition to uric acid nephrolithiasis. J Am Soc Nephrol 2006; 17:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/118\">",
"      Lee CT, Lien YH, Lai LW, et al. Increased renal calcium and magnesium transporter abundance in streptozotocin-induced diabetes mellitus. Kidney Int 2006; 69:1786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/119\">",
"      Maalouf NM, Sakhaee K, Parks JH, et al. Association of urinary pH with body weight in nephrolithiasis. Kidney Int 2004; 65:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/120\">",
"      Taylor EN, Curhan GC. Body size and 24-hour urine composition. Am J Kidney Dis 2006; 48:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/121\">",
"      Allen SE, Singh S, Robertson WG. The increased risk of urinary stone disease in betel quid chewers. Urol Res 2006; 34:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/122\">",
"      Taylor EN, Fung TT, Curhan GC. DASH-style diet associates with reduced risk for kidney stones. J Am Soc Nephrol 2009; 20:2253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/123\">",
"      Borghi L, Meschi T, Amato F, et al. Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-year randomized prospective study. J Urol 1996; 155:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/124\">",
"      Curhan GC, Willett WC, Knight EL, Stampfer MJ. Dietary factors and the risk of incident kidney stones in younger women: Nurses' Health Study II. Arch Intern Med 2004; 164:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/125\">",
"      Curhan GC, Willett WC, Speizer FE, Stampfer MJ. Beverage use and risk for kidney stones in women. Ann Intern Med 1998; 128:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/126\">",
"      Curhan GC, Willett WC, Rimm EB, et al. Prospective study of beverage use and the risk of kidney stones. Am J Epidemiol 1996; 143:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/127\">",
"      H&ouml;now R, Laube N, Schneider A, et al. Influence of grapefruit-, orange- and apple-juice consumption on urinary variables and risk of crystallization. Br J Nutr 2003; 90:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/128\">",
"      Trinchieri A, Lizzano R, Bernardini P, et al. Effect of acute load of grapefruit juice on urinary excretion of citrate and urinary risk factors for renal stone formation. Dig Liver Dis 2002; 34 Suppl 2:S160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/129\">",
"      Goldfarb DS, Asplin JR. Effect of grapefruit juice on urinary lithogenicity. J Urol 2001; 166:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/130\">",
"      Brinkley LJ, Gregory J, Pak CY. A further study of oxalate bioavailability in foods. J Urol 1990; 144:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/131\">",
"      Hirvonen T, Pietinen P, Virtanen M, et al. Nutrient intake and use of beverages and the risk of kidney stones among male smokers. Am J Epidemiol 1999; 150:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/132\">",
"      Helderman JH, Vestal RE, Rowe JW, et al. The response of arginine vasopressin to intravenous ethanol and hypertonic saline in man: the impact of aging. J Gerontol 1978; 33:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/133\">",
"      Eisenhofer G, Johnson RH. Effect of ethanol ingestion on plasma vasopressin and water balance in humans. Am J Physiol 1982; 242:R522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/134\">",
"      Wabner CL, Pak CY. Effect of orange juice consumption on urinary stone risk factors. J Urol 1993; 149:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/135\">",
"      Odvina CV. Comparative value of orange juice versus lemonade in reducing stone-forming risk. Clin J Am Soc Nephrol 2006; 1:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/136\">",
"      Gettman MT, Ogan K, Brinkley LJ, et al. Effect of cranberry juice consumption on urinary stone risk factors. J Urol 2005; 174:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/137\">",
"      Kessler T, Jansen B, Hesse A. Effect of blackcurrant-, cranberry- and plum juice consumption on risk factors associated with kidney stone formation. Eur J Clin Nutr 2002; 56:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/138\">",
"      McHarg T, Rodgers A, Charlton K. Influence of cranberry juice on the urinary risk factors for calcium oxalate kidney stone formation. BJU Int 2003; 92:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/139\">",
"      Lemann J Jr. Composition of the diet and calcium kidney stones. N Engl J Med 1993; 328:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/140\">",
"      Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006; 354:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/141\">",
"      Pak CY, Odvina CV, Pearle MS, et al. Effect of dietary modification on urinary stone risk factors. Kidney Int 2005; 68:2264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/142\">",
"      Siener R, H&ouml;now R, Voss S, et al. Oxalate content of cereals and cereal products. J Agric Food Chem 2006; 54:3008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/143\">",
"      Siener R, Ebert D, Nicolay C, Hesse A. Dietary risk factors for hyperoxaluria in calcium oxalate stone formers. Kidney Int 2003; 63:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/144\">",
"      Lieske JC, Tremaine WJ, De Simone C, et al. Diet, but not oral probiotics, effectively reduces urinary oxalate excretion and calcium oxalate supersaturation. Kidney Int 2010; 78:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/145\">",
"      Hess B, Jost C, Zipperle L, et al. High-calcium intake abolishes hyperoxaluria and reduces urinary crystallization during a 20-fold normal oxalate load in humans. Nephrol Dial Transplant 1998; 13:2241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/146\">",
"      Liebman M, Costa G. Effects of calcium and magnesium on urinary oxalate excretion after oxalate loads. J Urol 2000; 163:1565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/147\">",
"      Lemann J Jr, Pleuss JA, Gray RW, Hoffmann RG. Potassium administration reduces and potassium deprivation increases urinary calcium excretion in healthy adults [corrected]. Kidney Int 1991; 39:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/148\">",
"      Friedman PA, Gesek FA. Calcium transport in renal epithelial cells. Am J Physiol 1993; 264:F181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/149\">",
"      Muldowney FP, Freaney R, Moloney MF. Importance of dietary sodium in the hypercalciuria syndrome. Kidney Int 1982; 22:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/150\">",
"      Sakhaee K, Harvey JA, Padalino PK, et al. The potential role of salt abuse on the risk for kidney stone formation. J Urol 1993; 150:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/151\">",
"      Sorensen MD, Kahn AJ, Reiner AP, et al. Impact of nutritional factors on incident kidney stone formation: a report from the WHI OS. J Urol 2012; 187:1645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/152\">",
"      Kok DJ, Iestra JA, Doorenbos CJ, Papapoulos SE. The effects of dietary excesses in animal protein and in sodium on the composition and the crystallization kinetics of calcium oxalate monohydrate in urines of healthy men. J Clin Endocrinol Metab 1990; 71:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/153\">",
"      Breslau NA, Brinkley L, Hill KD, Pak CY. Relationship of animal protein-rich diet to kidney stone formation and calcium metabolism. J Clin Endocrinol Metab 1988; 66:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/154\">",
"      Amanzadeh J, Gitomer WL, Zerwekh JE, et al. Effect of high protein diet on stone-forming propensity and bone loss in rats. Kidney Int 2003; 64:2142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/155\">",
"      Hamm LL. Renal handling of citrate. Kidney Int 1990; 38:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/156\">",
"      Melnick JZ, Srere PA, Elshourbagy NA, et al. Adenosine triphosphate citrate lyase mediates hypocitraturia in rats. J Clin Invest 1996; 98:2381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/157\">",
"      Maalouf NM, Moe OW, Adams-Huet B, Sakhaee K. Hypercalciuria associated with high dietary protein intake is not due to acid load. J Clin Endocrinol Metab 2011; 96:3733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/158\">",
"      Hess B, Ackermann D, Essig M, et al. Renal mass and serum calcitriol in male idiopathic calcium renal stone formers: role of protein intake. J Clin Endocrinol Metab 1995; 80:1916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/159\">",
"      Holmes RP, Goodman HO, Hart LJ, Assimos DG. Relationship of protein intake to urinary oxalate and glycolate excretion. Kidney Int 1993; 44:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/160\">",
"      Lemann J Jr, Piering WF, Lennon EJ. Possible role of carbohydrate-induced calciuria in calcium oxalate kidney-stone formation. N Engl J Med 1969; 280:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/161\">",
"      Abate N, Chandalia M, Cabo-Chan AV Jr, et al. The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance. Kidney Int 2004; 65:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/162\">",
"      Levy FL, Adams-Huet B, Pak CY. Ambulatory evaluation of nephrolithiasis: an update of a 1980 protocol. Am J Med 1995; 98:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/53/33626/abstract/163\">",
"      Curhan GC, Willett WC, Speizer FE, Stampfer MJ. Twenty-four-hour urine chemistries and the risk of kidney stones among women and men. Kidney Int 2001; 59:2290.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7375 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-197.136.42.3-57354D163F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_53_33626=[""].join("\n");
var outline_f32_53_33626=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Hypercalciuria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Definition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Mechanisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Hyperoxaluria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Mechanisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Hypocitraturia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Mechanisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Hyperuricosuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Medullary sponge kidney",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Family history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Other factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DIETARY RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Fluid intake",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Type of fluid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Calcium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Oxalate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Potassium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Sodium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Protein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Phytate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Sucrose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      PREVALENCE OF URINARY RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7375\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7375|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/29/25053\" title=\"figure 1\">",
"      Protein intake and stones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7375|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?41/19/42302\" title=\"picture 1A\">",
"      Calcium oxalate crystals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?10/20/10561\" title=\"picture 1B\">",
"      Ca oxalate monohydrate crystals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7375|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/35/1596\" title=\"table 1\">",
"      Risk factors for calcium stones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/63/31739\" title=\"table 2\">",
"      Frequency biochem abnormalities",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/10/9378?source=related_link\">",
"      Chapter 4D: Tamm-Horsfall mucoprotein",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/58/41898?source=related_link\">",
"      Complications of bariatric surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/50/20266?source=related_link\">",
"      Diagnosis and acute management of suspected nephrolithiasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/44/18120?source=related_link\">",
"      Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/59/34746?source=related_link\">",
"      Etiology and evaluation of hematuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/22/29033?source=related_link\">",
"      Evaluation of the adult patient with established nephrolithiasis and treatment if stone composition is unknown",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/45/21209?source=related_link\">",
"      Hereditary hypophosphatemic rickets and tumor-induced osteomalacia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/21/37206?source=related_link\">",
"      Medullary sponge kidney",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/15/9462?source=related_link\">",
"      Metabolism of vitamin D",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/43/17081?source=related_link\">",
"      Nephrocalcinosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/26/23973?source=related_link\">",
"      Nephrolithiasis in renal tubular acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/53/28499?source=related_link\">",
"      Patient information: Kidney stones in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/2/38953?source=related_link\">",
"      Prevention of recurrent calcium stones in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/55/12154?source=related_link\">",
"      Primary hyperoxaluria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/31/33274?source=related_link\">",
"      Surgical management of severe obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/18/39201?source=related_link\">",
"      Triamterene nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/62/3047?source=related_link\">",
"      Uric acid nephrolithiasis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_53_33627="Drug properties MAOIs";
var content_f32_53_33627=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F78169&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F78169&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drug properties of monoamine oxidase inhibitor antidepressants and dosages in the elderly (See note)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Starting dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose range for older adult",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isocarboxazid",
"       </td>",
"       <td>",
"        10 mg every morning",
"       </td>",
"       <td>",
"        10 to&nbsp;40 mg per day in divided doses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phenelzine",
"       </td>",
"       <td>",
"        7.5 mg every morning",
"       </td>",
"       <td>",
"        22.5&nbsp;to&nbsp;60 mg per day in&nbsp;three divided&nbsp;doses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tranylcypromine",
"       </td>",
"       <td>",
"        10 mg every morning",
"       </td>",
"       <td>",
"        10 to 40 mg per day&nbsp;in divided doses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Selegiline (transdermal patch)",
"       </td>",
"       <td>",
"        6 mg/24 hours applied&nbsp;once daily",
"       </td>",
"       <td>",
"        6&nbsp;to 12 mg/24 hours applied once daily",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    MAOI: monoamine oxidase inhibitors",
"    <br>",
"     IMPORTANT NOTE: MAOIs are",
"     <strong>",
"      NOT",
"     </strong>",
"     first line antidepressant medications due to the dietary restrictions, drug-drug interactions and potentially severe side-effects.&nbsp; MAOIs are rarely used in medically ill or older adults except when previously initiated and tolerated in the patient who is treatment resistant to all other antidepressants.&nbsp; For specific drug interactions see the Lexi-Interact program included with UpToDate. For additional information, refer to the separate topic on MAOIs for treating depressed adults.",
"     <div class=\"footnotes\">",
"      <p>",
"       &nbsp;",
"      </p>",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_53_33627=[""].join("\n");
var outline_f32_53_33627=null;
var title_f32_53_33628="Nasogastric tubes";
var content_f32_53_33628=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F52488&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F52488&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Nasogastric tubes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Tube",
"       </td>",
"       <td class=\"subtitle1\">",
"        Sizes",
"       </td>",
"       <td class=\"subtitle1\">",
"        Length",
"       </td>",
"       <td class=\"subtitle1\">",
"        Lumen",
"       </td>",
"       <td class=\"subtitle1\">",
"        Function",
"       </td>",
"       <td class=\"subtitle1\">",
"        Material",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Salem-sump",
"       </td>",
"       <td rowspan=\"3\">",
"        6-18 F",
"       </td>",
"       <td rowspan=\"3\">",
"        60-122 cm",
"       </td>",
"       <td rowspan=\"3\">",
"        Double",
"       </td>",
"       <td>",
"        Gastric decompression",
"       </td>",
"       <td rowspan=\"3\">",
"        PVC",
"       </td>",
"       <td rowspan=\"3\">",
"        Second lumen vents to atmosphere to prevent suctioning of tube to gastric mucosa. Radio opaque line along its length.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medication delivery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enteral feeding",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Levin tube",
"       </td>",
"       <td rowspan=\"3\">",
"        8-20 F",
"       </td>",
"       <td rowspan=\"3\">",
"        122 cm",
"       </td>",
"       <td rowspan=\"3\">",
"        Single",
"       </td>",
"       <td>",
"        Gastric decompression",
"       </td>",
"       <td rowspan=\"3\">",
"        PVC",
"       </td>",
"       <td rowspan=\"3\">",
"        Markings at 45, 55, 65, 75 cm. Radio opaque line along its length.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medication delivery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enteral feeding",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Ryle's tube",
"       </td>",
"       <td rowspan=\"2\">",
"        8-20 F",
"       </td>",
"       <td rowspan=\"2\">",
"        105 cm",
"       </td>",
"       <td rowspan=\"2\">",
"        Single",
"       </td>",
"       <td>",
"        Gastric aspiration",
"       </td>",
"       <td rowspan=\"2\">",
"        PVC",
"       </td>",
"       <td rowspan=\"2\">",
"        Markings at 50, 60, 70 cm. Radio opaque line along its length. Weighted end.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enteral feeding",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         Enteral feeding tubes",
"        </p>",
"        <p>",
"         (Examples: Abbot Nutrition enteral feeding tube; Cook Endoscopy NJFT; Corpak Medical Systems CORFLO tubes; Covidien tubes; Teleflex Medical tubes)",
"        </p>",
"       </td>",
"       <td>",
"        3.5-12 F",
"       </td>",
"       <td>",
"        31-240 cm",
"       </td>",
"       <td>",
"        Single to triple",
"       </td>",
"       <td>",
"        Enteral feeding",
"       </td>",
"       <td>",
"        Polyurethane, silicone, PVC",
"       </td>",
"       <td>",
"        Various features may be present:",
"        <ul>",
"         <li>",
"          Stylet used for &lt;12 F tubes to stiffen the tube for insertion and confirm placement radiographically",
"         </li>",
"         <li>",
"          Radio opaque markers each cm",
"         </li>",
"         <li>",
"          Weighted tip to allow propulsion into duodenum by peristalsis",
"         </li>",
"         <li>",
"          Magnets to facilitate jejunal placement",
"         </li>",
"         <li>",
"          Suture loops to allow endoscopic placement",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PVC: polyvinyl chloride.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_53_33628=[""].join("\n");
var outline_f32_53_33628=null;
var title_f32_53_33629="Oxidized LDL endothelial injury";
var content_f32_53_33629=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F72955&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F72955&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 505px\">",
"   <div class=\"ttl\">",
"    Linkage between lipid infiltration and endothelial injury in atherosclerosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 485px; height: 244px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Oxidized LDL in atherosclerosis. Postulated linkage between oxidized LDL and endothelial injury in the pathogenesis of atherosclerosis. Lipid- infiltration may be sufficient to account for fatty streaks (left column), while endothelial injury (right column) may account for progression of the fatty streak to more advanced lesions.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Steinberg, D, Parthasarathy, S, Carew, TE, et al, N Engl J Med 1989; 320:915.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_53_33629=[""].join("\n");
var outline_f32_53_33629=null;
var title_f32_53_33630="Algorithm for vascular testing in symptomatic PAD";
var content_f32_53_33630=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F50445&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F50445&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 574px\">",
"   <div class=\"ttl\">",
"    Algorithm for vascular testing in symptomatic PAD",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 554px; height: 348px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patients with diabetes or end-stage renal disesae may have falsely elevated ABIs as a result of arterial calcification. The toe-brachial index may be more accurate.",
"    <div class=\"footnotes\">",
"     ABI: ankle brachial index; PAD: peripheral artery disease; MRA: magnetic resonance angiography; CTA: computed tomographic angiography.",
"     <br/>",
"     * Diagnostic for PAD.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_53_33630=[""].join("\n");
var outline_f32_53_33630=null;
var title_f32_53_33631="U wave inversion";
var content_f32_53_33631=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F59743&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F59743&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Exercise-induced U wave inversion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 411px; height: 267px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    At rest (blue panel), the U waves are upright in leads V2, V4, and V5 on the surface electrocardiogram. One minute into exercise (green panel), there is evidence of U wave inversion in this patient with severe multivessel coronary heart disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_53_33631=[""].join("\n");
var outline_f32_53_33631=null;
